

**(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. AU 2003299972 C1

(54) Title
Methods and reagents for the enhancement of virus transduction in the bladder epithelium

(51) International Patent Classification(s)
A61K 31/7024 (2006.01) **A61K 45/06** (2006.01)
A61K 9/00 (2006.01) **A61K 47/10** (2006.01)
A61K 31/337 (2006.01) **A61K 47/26** (2006.01)
A61K 35/76 (2006.01) **A61K 48/00** (2006.01)

(21) Application No: **2003299972** (22) Date of Filing: **2003.12.24**

(87) WIPO No: **WO04/060303**

(30) Priority Data

(31) Number **10/327,869** (32) Date **2002.12.26** (33) Country **US**

(43) Publication Date: **2004.07.29**
(43) Publication Journal Date: **2004.09.02**
(44) Accepted Journal Date: **2010.05.13**
(44) Amended Journal Date: **2010.12.16**

(71) Applicant(s)
BioSante Pharmaceuticals, Inc

(72) Inventor(s)
Memarzadeh, Bahram;Ramesh, Nagarajan;Frey, David;Yu, DeChao

(74) Agent / Attorney
A J PARK, Level 11 60 Marcus Clarke Street, Canberra, ACT, 2601

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 July 2004 (22.07.2004)

PCT

(10) International Publication Number
WO 2004/060303 A2

(51) International Patent Classification⁷: A61K

(21) International Application Number: PCT/US2003/041379

(22) International Filing Date: 24 December 2003 (24.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 10/327,869 26 December 2002 (26.12.2002) US

(71) Applicant: CELL GENESYS, INC. [US/US]; 500 Forbes Boulevard, South San Francisco, CA 94080 (US).

(72) Inventors: RAMESH, Nagarajan; 883 W. Homestead Road, Sunnyvale, CA 94087 (US). FREY, David; 545 Palma Street, Half Moon Bay, CA 94019 (US). MEMARZADEH, Bahram; 574 Chestnut Street #6, San Carlos, CA 94070 (US). YU, DeChao; 352 Dolphin Isle, Foster City, CA 94404 (US).

(74) Agents: KELBER, Steven, B. et al.; Piper Rudnick LLP, 1200 Nineteenth Street N.W., Washington, DC 20036 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND REAGENTS FOR THE ENHANCEMENT OF VIRUS TRANSDUCTION IN THE BLADDER EPITHELIUM



WO 2004/060303 A2

(57) Abstract: Agents and methods for enhancing recombinant virus transduction in the bladder epithelium are described. A first method involves contacting the luminal surface of the bladder with a composition comprising a transduction enhancing agent and an oncolytic virus. Alternatively, the luminal surface of the bladder can be contacted first with a pretreatment composition comprising a transduction enhancing agent and, subsequently, with a composition comprising an oncolytic virus. Bladder treatment compositions comprising a transduction enhancing agent and an oncolytic virus are also described.

TITLE OF THE INVENTION**METHODS AND REAGENTS FOR THE ENHANCEMENT OF VIRUS
TRANSDUCTION IN THE BLADDER EPITHELIUM**

This application is a continuation-in-part of U.S. Patent Application Serial No. 10/327,869, filed December 26, 2002, which application is incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION**Field of the Invention**

The present invention relates generally to the treatment of bladder cancer with viral therapy agents and, in particular, to agents and methods for enhancing recombinant oncolytic virus transduction of the bladder epithelium.

Background of the Technology

Bladder cancer is a commonly occurring cancer and more than 50,000 new cases are diagnosed every year. Bladder cancer is a superficial disease confined to the mucosa in the majority of patients. Of the various therapeutic modalities available, transurethral resectioning of the tumor is considered to be the most effective treatment for the management of superficial bladder cancer. However, 70% of these superficial bladder tumors will recur after endoscopic resectioning, and 20% progress to life-threatening invasive diseases within 2 years of cystectomy. See Raghavan, et al., "Biology and Management of Bladder Cancer", N. Engl. J. Med., 322, 16, 1129-1138 (1990).

Gene therapy has also been used for the treatment of bladder cancer. See, for example, Brewster, et al., Eur. Urol. 25, 177-182 (1984); Takahashi, et al., Proc. Natl. Acad. Sci. USA 88, 5257-5261 (1991); and Rosenberg, J. Clin. Oncol., 10, 180-199 (1992).

In vitro studies using cell lines derived from human bladder tissues have demonstrated efficient transgene expression following infection with recombinant adenovirus. Bass, et al., Cancer Gene Therapy 2, 2, 97-104 (1995). Experiments *in vivo* have also shown adenovirus transgene expression in the urinary bladder of

12 Apr 2010

2003299972

WO 2004/060303

PCT/US2003/041379

rodents after intravesical administration. Bass, et al., supra; Morris, et al., J. Urology, 152, 506-550 (1994). *In vitro* experiments with wild-type adenovirus demonstrate that virus attachment and internalization is not influenced by benzyl alcohol, but do demonstrate an enhanced uncoating of the virion. Blixt, et al., Arch. Virol., 129, 265-277 (1993).

5 *In vivo* studies have demonstrated that various agents (e.g. acetone, DMSO, protamine sulfate) can break down the protective "mucin" layer that protects the bladder epithelium from bacteria, viruses and other pathogens. See, for example, Monson, et al., J. Urol., 145, 842-845 (1992) and Parsons, et al., J. Urol., 143, 139-142 (1990). Methods of modifying the bladder surface to enhance gene transfer have also been disclosed. Siemens, et al., "Evaluation of Gene Transfer Efficiency by Viral Vectors to Murine Bladder Epithelium", J. of Urology, 165, 667-671 (2001).

10 U.S. Patent No. 6,165,779 discloses a gene delivery system formulated in a buffer comprising a delivery-enhancing agent such as ethanol or a detergent. The gene delivery system may be a recombinant viral vector such as an adenoviral vector.

15 There still exists a need, however, for improved gene therapy methods and agents which can accomplish direct, optimal, *in vivo* gene delivery to the bladder epithelium.

20 It is an object of the present invention to go some way towards meeting this need and/or to provide the public with a useful choice.

SUMMARY OF THE INVENTION


25 According to a first aspect, the invention provides a method for treating cancer of the bladder comprising:

contacting the luminal surface of the bladder with a pretreatment composition comprising a transduction enhancing agent, either together with a composition comprising an oncolytic virus or before contacting the luminal surface of the bladder with a composition comprising an oncolytic virus;

12 Apr 2010

2003299972

wherein the transduction enhancing agent is a disaccharide having a lipophilic substituent and wherein the disaccharide is selected from the group consisting of sucrose, lactose, maltose, isomaltose, trehalose and cellobiose. The transduction enhancing agent can have the following general formula (I) or the following general formula (II):





12 Apr 2010


2003299972

WO 2004/060303

PCT/US2003/041379



wherein X is a sulfur or oxygen atom, R¹ is an alkyl group and each R² is independently hydrogen or a moiety represented by:



wherein R¹ is an alkyl group. The pretreatment composition can further include an oxidizing agent. The oncolytic virus can be an oncolytic adenovirus such as

5 CG8840. The oncolytic virus composition can further include a chemotherapeutic agent such as docetaxel.


According to a second aspect, the invention provides a method for treating cancer of the bladder comprising:

10 contacting the luminal surface of the bladder with a pretreatment composition comprising about 0.01 to about 0.2 % by weight sodium oxychlorosene, either together with a composition comprising an oncolytic virus or before contacting the luminal surface of the bladder with a composition comprising an oncolytic virus.

15

2003299972 12 Apr 2010

According to a third aspect, the invention provides the bladder comprising:
contacting the luminal surface of the bladder with a pretreatment
composition comprising a transduction enhancing agent having a structure
represented by the chemical formula:





12 Apr 2010

2003299972

wherein x and y are positive integers; wherein the luminal surface of the bladder is contacted with the pretreatment composition either together with a composition comprising an oncolytic virus or before the luminal surface of the bladder is contacted with a composition comprising an oncolytic virus. According to a preferred embodiment of the invention, x is 6 and y is 8-10 and the pretreatment composition comprises about 0.02 to about 0.05 wt.% of the transduction enhancing agent.

According to a fourth aspect, the invention provides a method of treating cancer of the bladder comprising:

contacting the luminal surface of the bladder with a pretreatment composition comprising a transduction enhancing agent having a structure represented by the following general formula (I) or the following general formula (II):




wherein x is a positive integer; wherein the luminal surface of the bladder is contacted with the pretreatment composition either together with a composition comprising an oncolytic virus or before the luminal surface of the bladder is contacted with a composition comprising an oncolytic virus.

According to a fifth aspect, the invention provides a composition comprising:
a transduction enhancing agent; and
an oncolytic virus;
wherein the transduction enhancing agent is a disaccharide having a


12 Apr 2010

2003299972

lipophilic substituent and wherein the disaccharide is selected from the group consisting of sucrose, lactose, maltose, isomaltose, trehalose and cellobiose, wherein the composition comprises (1) a single composition comprising the transduction enhancing agent and the oncolytic virus or (2) a first composition comprising the transduction enhancing agent and a second composition comprising the oncolytic virus. For example, the transduction enhancing agent can be a compound having the following general formula (I) or the following general formula (II):



wherein X is a sulfur or oxygen atom, R¹ is an alkyl group and each R² is independently hydrogen or a moiety represented by:



wherein R¹ is an alkyl group. The oncolytic virus can be an oncolytic adenovirus such as CG8840. The oncolytic virus composition can further include a chemotherapeutic agent such as docetaxel. A method for treating cancer of the bladder comprising contacting the luminal surface of the bladder with a composition as set forth above is also provided.

12 Apr 2010

2003299972



According to a sixth aspect, the invention provides a composition comprising:

a transduction enhancing agent, wherein the transduction enhancing agent is sodium oxychlorosene, and an oncolytic virus, wherein the composition comprises (1) a single composition comprising the transduction enhancing agent and the oncolytic virus or (2) a first composition comprising the transduction enhancing agent and a second composition comprising the oncolytic virus. The oncolytic virus can be an oncolytic adenovirus such as CG8840. The oncolytic virus composition can further include a chemotherapeutic agent such as docetaxel.

According to a seventh aspect, the invention provides a composition comprising a transduction enhancing agent; and

an oncolytic virus;

wherein the transduction enhancing agent has a structure represented by the following general formula (I) or the following general formula (II):




wherein x is a positive integer and wherein the concentration of the transduction enhancing agent is less than 0.025 wt% of the composition,

wherein the composition comprises (1) a single composition comprising the transduction enhancing agent and the oncolytic virus or (2) a first composition comprising the transduction enhancing agent and a second composition comprising the oncolytic virus.

12 Apr 2010

2003299972

According to an eighth aspect, the invention provides a transduction enhancing agent and an oncolytic virus, wherein the transduction enhancing agent has a structure represented by the chemical formula:



wherein x and y are positive integers, and wherein the composition comprises (1) a single composition comprising the transduction enhancing agent and the oncolytic virus or (2) a first composition comprising the transduction enhancing agent and a second composition comprising the oncolytic virus.

A method for treating cancer of the bladder comprising contacting the luminal surface of the bladder with a composition as set forth above is also provided.

The term "comprising" as used in this specification and claims means "consisting at least in part of". When interpreting statements in this specification and claims which include "comprising", other features besides the features prefaced by this term in each statement can also be present. Related terms such as "comprise" and "comprised" are to be interpreted in similar manner.

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention may be better understood with reference to the accompanying drawings in which:

FIGS. 1A and 1B are photographs showing a murine bladder after 5 pretreatment with a 15 % ethanol solution followed by infection with Ad-LacZ wherein FIG. 1A shows the outside surface of the bladder and FIG. 1B shows the luminal bladder surface;

FIGS. 1C and 1D are photographs showing a murine bladder after 10 pretreatment with a 20 % ethanol solution followed by infection with Ad-LacZ wherein FIG. 1C shows the outside surface of the bladder and FIG. 1D shows the luminal bladder surface;

FIGS. 1E and 1F are photographs showing a murine bladder after 15 pretreatment with a 25% ethanol solution followed by infection with Ad-LacZ wherein FIG. 1E shows the outside surface of the bladder and FIG. 1F shows the luminal bladder surface;

FIGS. 1G and 1H are photographs showing a murine bladder after pretreatment with a 30 % ethanol solution followed by infection with Ad-LacZ wherein FIG. 1G shows the outside surface of the bladder and FIG. 1H shows the luminal bladder surface;

20 FIG. 2A is a photograph showing a cross section of a murine bladder control;

FIGS. 2B and 2C are photographs showing the cross section of a murine bladder after pretreatment with a 30 % ethanol solution followed by infection with Ad-LacZ;

25 FIGS. 3A-3F are photographs showing the cross section of a murine bladder after pretreatment with a 25 % ethanol solution followed by infection with Ad-LacZ wherein FIGS. 3A, 3C and 3E were taken at 40X and FIGS. 3B, 3D and 3F were taken at 100X magnification;

30 FIGS. 4A-4F are photographs showing the cross section of a murine bladder after pretreatment with a 30 % ethanol solution followed by infection with

Ad-LacZ wherein FIGS. 4A, 4C and 4E were taken at 40X and FIGS. 4B, 4D and 4F were taken at 100X magnification;

FIGS. 5A-5D are photographs showing two murine bladders after pretreatment with a 4 % poloxomer 407 solution followed by infection with Ad-
5 LacZ wherein FIGS. 5A and 5B show the outside and luminal surfaces, respectively, of the first bladder and FIGS. 5C and 5D show the outside and luminal surfaces, respectively, of the second bladder;

FIGS. 6A-6D are photographs showing two murine bladders after infection with a composition comprising lipofectamine and Ad-LacZ wherein FIGS. 6A and 10 6B show the outside and luminal surfaces, respectively, of the first bladder and FIGS. 6C and 6D show the outside and luminal surfaces, respectively, of the second bladder;

FIGS. 7A-7D are photographs showing two murine bladders after infection with a composition comprising *In vivo* geneSHUTTLE™ and Ad-LacZ wherein 15 FIGS. 7A and 7B show the outside and luminal surfaces, respectively, of the first bladder and FIGS. 7C and 7D show the outside and luminal surfaces, respectively, of the second bladder;

FIGS. 8A-8N are photographs showing seven murine bladders after pretreatment with a 0.2 % oxychlorosene solution for 5 minutes followed by 20 infection with Ad-LacZ wherein FIGS. 8A and 8B show the outside and luminal surfaces, respectively, of the first bladder, FIGS. 8C and 8D show the outside and luminal surfaces, respectively, of the second bladder, FIGS. 8E and 8F show the outside and luminal surfaces, respectively, of the third bladder, FIGS. 8G and 8H show the outside and luminal surfaces, respectively, of the fourth bladder, FIGS. 8I 25 and 8J show the outside and luminal surfaces, respectively, of the fifth bladder, FIGS. 8K and 8L show the outside and luminal surfaces, respectively, of the sixth bladder, and FIGS. 8M and 8N show the outside and luminal surfaces, respectively, of the seventh bladder;

FIGS. 9A-9N are photographs showing seven murine bladders after 30 pretreatment with a 0.2 % oxychlorosene solution for 15 minutes followed by

infection with Ad-LacZ wherein FIGS. 9A and 9B show the outside and luminal surfaces, respectively, of the first bladder, FIGS. 9C and 9D show the outside and luminal surfaces, respectively, of the second bladder, FIGS. 9E and 9F show the outside and luminal surfaces, respectively, of the third bladder, FIGS. 9G and 9H show the outside and luminal surfaces, respectively, of the fourth bladder, FIGS. 9I and 9J show the outside and luminal surfaces, respectively, of the fifth bladder, FIGS. 9K and 9L show the outside and luminal surfaces, respectively, of the sixth bladder, and FIGS. 9M and 9N show the outside and luminal surfaces, respectively, of the seventh bladder;

FIGS. 10A and 10B are photographs showing the cross section of the murine bladders of FIGS. 8C and 8I, respectively;

FIGS. 11A and 11B are photographs showing the cross section of the murine bladders of FIGS. 9C and 9I, respectively;

FIGS. 12A-12F are photographs showing the cross section of a murine bladder after pretreatment with a 0.2 % oxychlorosene solution for 5 minutes followed by infection with Ad-LacZ wherein FIGS. 12A, 12C and 12E were taken at 40X and FIGS. 12B, 12D and 12F were taken at 100X magnification;

FIGS. 13A-13F are photographs showing the cross section of a murine bladder after pretreatment with a 0.2 % oxychlorosene solution for 15 minutes followed by infection with Ad-LacZ wherein FIGS. 13A, 13C and 13E were taken at 40X and FIGS. 13B, 13D and 13F were taken at 100X magnification;

FIG. 14A is a photograph showing the luminal surface of a murine bladder after pretreatment with a 0.1 % oxychlorosene solution followed by infection with Ad-LacZ;

FIGS. 14B and 14C are photographs showing the cross section of the murine bladder of FIG. 14A wherein FIG. 14B was taken at 40X and FIG. 14C was taken at 100X magnification;

FIG. 15A is a photograph showing the luminal surface of a first murine bladder after pretreatment with a 0.2 % oxychlorosene solution followed by infection with Ad-LacZ;

FIGS. 15B and 15C are photographs showing the cross section of the murine bladder of FIG. 15A wherein FIG. 15B was taken at 40X and FIG. 15C was taken at 100X magnification;

5 FIG. 16A is a photograph showing the luminal surface of a second murine bladder after pretreatment with a 0.2 % oxychlorosene solution followed by infection with Ad-LacZ;

FIGS. 16B and 16C are photographs showing the cross section of the murine bladder of FIG. 16A wherein FIG. 16B was taken at 40X and FIG. 16C was taken at 100X magnification;

10 FIG. 17A is a photograph showing the luminal surface of a first murine bladder after pretreatment with a 0.4 % oxychlorosene solution followed by infection with Ad-LacZ;

15 FIGS. 17B and 17C are photographs showing the cross section of the murine bladder of FIG. 17A wherein FIG. 17B was taken at 40X and FIG. 17C was taken at 100X magnification;

FIG. 18A is a photograph showing the luminal surface of a second murine bladder after pretreatment with a 0.4 % oxychlorosene solution followed by infection with Ad-LacZ;

20 FIGS. 18B and 18C are photographs showing the cross section of the murine bladder of FIG. 18A wherein FIG. 18B was taken at 40X and FIG. 18C was taken at 100X magnification;

FIG. 19A is a photograph showing the luminal surface of a first murine bladder after pretreatment with a 0.02 % polidocanol solution followed by infection with Ad-LacZ;

25 FIGS. 19B and 19C are photographs showing the cross section of the murine bladder of FIG. 19A wherein FIG. 19B was taken at 40X and FIG. 19C was taken at 100X magnification;

30 FIG. 20A is a photograph showing the luminal surface of a second murine bladder after pretreatment with a 0.02 % polidocanol solution followed by infection with Ad-LacZ;

FIGS. 20B and 20C are photographs showing the cross section of the murine bladder of FIG. 20A wherein FIG. 20B was taken at 40X and FIG. 20C was taken at 100X magnification;

5 FIG. 21A and 21B are photographs showing the outside and luminal surfaces, respectively, of a first murine bladder after pretreatment with a 0.05 % polidocanol solution followed by infection with Ad-LacZ;

FIGS. 21C and 21D are photographs showing the cross section of the murine bladder of FIG. 21A wherein FIG. 21B was taken at 40X and FIG. 21C was taken at 100X magnification;

10 FIG. 22A and 22B are photographs showing the outside and luminal surfaces, respectively, of a second murine bladder after pretreatment with a 0.05 % polidocanol solution followed by infection with Ad-LacZ;

15 FIGS. 22C and 22D are photographs showing the cross section of the murine bladder of FIG. 22A wherein FIG. 22B was taken at 40X and FIG. 22C was taken at 100X magnification;

FIG. 23A is a photograph showing the luminal surface of a first murine bladder after pretreatment with a 0.2 % polidocanol solution followed by infection with Ad-LacZ;

20 FIGS. 23B and 23C are photographs showing the cross section of the murine bladder of FIG. 23A wherein FIG. 23B was taken at 40X and FIG. 23C was taken at 100X magnification;

FIG. 24A is a photograph showing the luminal surface of a second murine bladder after pretreatment with a 0.2 % polidocanol solution followed by infection with Ad-LacZ;

25 FIGS. 24B and 24C are photographs showing the cross section of the murine bladder of FIG. 24A wherein FIG. 24B was taken at 40X and FIG. 24C was taken at 100X magnification;

FIG. 25A is a photograph showing the luminal surface of a first murine bladder after pretreatment with a 0.02 % n-dodecyl β -D-maltoside solution followed by infection with Ad-LacZ;

FIGS. 25B and 25C are photographs showing the cross section of the murine bladder of FIG. 25A wherein FIG. 25B was taken at 40X and FIG. 25C was taken at 100X magnification;

5 FIG. 26A is a photograph showing the luminal surface of a second murine bladder after pretreatment with a 0.02 % n-dodecyl β -D-maltoside solution followed by infection with Ad-LacZ;

FIGS. 26B and 26C are photographs showing the cross section of the murine bladder of FIG. 26A wherein FIG. 26B was taken at 40X and FIG. 26C was taken at 100X magnification;

10 FIG. 27A is a photograph showing the luminal surface of a first murine bladder after pretreatment with a 0.05 % n-dodecyl β -D-maltoside solution followed by infection with Ad-LacZ;

15 FIGS. 27B and 27C are photographs showing the cross section of the murine bladder of FIG. 27A wherein FIG. 27B was taken at 40X and FIG. 27C was taken at 100X magnification;

FIG. 28A is a photograph showing the luminal surface of a first murine bladder after pretreatment with a 0.05 % n-dodecyl β -D-maltoside solution followed by infection with Ad-LacZ;

20 FIGS. 28B and 28C are photographs showing the cross section of the murine bladder of FIG. 28A wherein FIG. 28B was taken at 40X and FIG. 28C was taken at 100X magnification;

FIG. 29A is a photograph showing the luminal surface of a first murine bladder after pretreatment with a 0.2 % n-dodecyl β -D-maltoside solution followed by infection with Ad-LacZ;

25 FIGS. 29B and 29C are photographs showing the cross section of the murine bladder of FIG. 29A wherein FIG. 29B was taken at 40X and FIG. 29C was taken at 100X magnification;

30 FIG. 30A is a photograph showing the luminal surface of a first murine bladder after pretreatment with a 0.2 % sodium salt of dedecyl benzenesulfonic acid solution followed by infection with Ad-LacZ;

FIGS. 30B and 30C are photographs showing the cross section of the murine bladder of FIG. 30A wherein FIG. 30B was taken at 40X and FIG. 30C was taken at 100X magnification;

5 FIGS. 31A-31E are photographs showing the luminal surfaces of murine bladders treated with alkyl maltoside and alkyl maltopyranoside pretreating agents having various length alkyl side chains; and

FIGS. 32A-32C are photographs showing the luminal surfaces of murine bladders treated with sodium alkyl sulfate pretreating agents having various length alkyl chains.

10 **DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS**

The present invention is directed to the use of transduction enhancing agents to render the bladder umbrella cell layer more susceptible to infection with a viral gene delivery vehicle than it would be without treatment. Exemplary transduction enhancing agents according to the invention include: dodecyl surfactants; dodecylmaltosides; dodecyl alcohol polyoxyethylene ethers (i.e., polidocanol); and sodium dodecylbenzenesulphonic acid/hypochlorous acid complex (i.e., oxychlorosene).

According to the invention, the luminal surface of the bladder can be treated with a composition comprising a transduction enhancing agent prior to 20 infection with a viral gene delivery vehicle. The viral gene delivery vehicle can be an oncolytic virus used to treat bladder cancer. Oncolytic viruses for use in practicing the invention include, but are not limited to, adenovirus, herpes simplex virus (HSV), reovirus, vesicular stomatitis virus (VSV), newcastle disease virus, vaccinia virus, influenza virus, West Nile virus, coxsackie virus, poliovirus and 25 measles virus. Of particular interest in practicing the invention are oncolytic viruses that exhibit preferential expression in particular tissue types (i.e., in the bladder urothelium). An oncolytic adenovirus of this type is disclosed, for example, in Zhang, et al., "Identification of Human Uroplakin II Promoter and Its Use in the Construction of CG8840, a Urothelium-specific Adenovirus Variant that 30 Eliminates Established Bladder Tumors in Combination with Docetaxel", Cancer

Research, 62, 3743-3750 (2002) and in co-owned U.S. Patent Application Serial No. 09/814,292, which is expressly incorporated by reference herein.

Chemotherapeutic agents for use in combination therapy with oncolytic viruses are described, for example, in co-owned U.S. Patent Application Serial No.

5 09/814,357, which is expressly incorporated by reference herein.

Alternatively, the viral gene delivery vehicle can be any gene therapy delivery vehicle known in the art for use in gene therapy, including, but not limited to, an adenovirus, an adeno-associated virus (AAV), a lentivirus, a retrovirus, a herpes virus, etc. Exemplary gene therapy adenoviral agents are disclosed in U.S. 10 Patent No. 6,165,779. The present inventors have found that pre-treating mouse bladders with aqueous solutions of various compounds consistently increased transduction to greater than 60 % of the bladder surface, versus an untreated percent transduction of no more than 10 %.

In addition to pre-treatment of the bladder surface with the transduction enhancing agent, the present invention includes co-administration of the viral gene 15 delivery vehicle and the transduction enhancing agent to the bladder and to co-formulations of any one of the transduction enhancing agents with a recombinant viral gene delivery vehicle.

20 ***Composition and Chemistry of Reagents Used to Enhance Adenovirus Transduction in the Bladder Epithelium***

Several classes of compounds, surfactants, and pre-made reagents were 25 tested in order to find those which increased gene transfer or transduction by a viral gene delivery vehicle in the bladder. An oncolytic adenovirus, CG884, was used as an exemplary viral gene therapy vehicle. The reagents evaluated can be classified by their physical or chemical properties and structure.

First, the reagents can be grouped as a single compound or as a mixed reagent (i.e., a mixture of compounds). Single compounds evaluated include non-ionic surfactants, alcohols, polymers and ionic surfactants. The ionic surfactants evaluated included: 4% Poloxamer 407 (Pluronic® 127); 4% poloxamer 188

(Pluronic® F68); 0.02%-0.5% Polidocanol; 0.1% n-dodecyl-b-D-glucopyranoside (which can also be classified as a sugar-based surfactant); 0.02-0.5% n-dodecyl-b-D-maltoside (which can also be classified as a sugar-based surfactant); 0.1% Tween® 20; 0.1% Triton® X-100; 0.1% Forlan® C-24 (PEG Cholesterol); 0.1% 5 decyl-b-D-maltoside (which can also be classified as a sugar-based surfactant); 0.1 % 6-cyclohexylhexyl-β-D-maltoside (which can also be classified as a sugar-based surfactant); and 0.1% Tromboject® (sodium tetradecyl sulfate).

Alcohols evaluated include 0.1 % - 3 % benzyl alcohol and 10 % -30 % ethanol. Polymers evaluated include 0.4 % HPMC 2910; 0.4 % PVA; 0.4 % PVP; 10 and 100 mg/ml Poly-Lysine. Ionic surfactants evaluated include: 0.1% DC-Chol [Cholesteryl 3b-N-(dimethylaminoethyl) carbamate]; 0.2 % sodium salt of Dodecyl benzenesulfonic acid; and 0.1 % sodium dodecyl sulfate. Mixed reagents evaluated include: *In vivo* GeneSHUTTLE™ (a reagent comprising DOTAP + Cholesterol available from Qbiogene of Carlsbad, CA) and 0.1%-0.4% 15 Oxychlorosene (sodium dodecylbenzenesulphonic acid/hypochlorous acid complex).

Effect of Ethanol pretreatment on Adenovirus-Mediated Gene Transfer and Expression in The Bladder Epithelium of Rodents

A study was conducted to evaluate the effect of ethanol pretreatment on 20 adenovirus-mediated gene transfer and expression in the bladder epithelium of rodents.

Test Materials

Ad-βgal virus was made as a frozen formulation using standard conditions known in the art for freezing and formulation of adenovirus. The vehicle for the 25 virus arm was PBS plus 10% glycerol. Pretreatment agents were 5 %, 10 %, 15 %, 20 % and 30 % GLP grade ethanol, respectively, in PBS-10 % glycerol solution.

Animals

80 female BALB/c mice were used for this study. Female animals are chosen because of the ease of urethral cannulation and vesicle instillation. The 30 mice were approximately 10 to 12 weeks on the day of the start of the experiment.

Treatment Regimen

Animals were assigned to each group as shown in the following table.

Table 1: Effect of Ethanol pretreatment

5	Group No.	Animals per group	Test Article	Route	Ethanol pre-treatment	Virus dose (particles/animal)	Dose Regimen
10	1	8-10	Vehicle	Intravesical	-	-	100 ml PBS-10% glycerol on Day 1
	2	8-10	Ad- β gal	Intravesical	-	1.3×10^{11}	Ad- β gal on Day 1
	3	8-10	Ad- β gal	Intravesical	5% ethanol	1.3×10^{11}	5% ethanol pretreatment followed by virus administration on Day 1
	4	8-10	Ad- β gal	Intravesical	10% ethanol	1.3×10^{11}	10% ethanol pretreatment followed by virus administration on Day 1
	5	8-10	Ad- β gal	Intravesical	15% ethanol	1.3×10^{11}	15% ethanol pretreatment followed by virus administration on Day 1
	6	8-10	Ad- β gal	Intravesical	20% ethanol	1.3×10^{11}	20% ethanol pretreatment followed by virus administration on Day 1
	7	8-10	Ad- β gal	Intravesical	25% ethanol	1.3×10^{11}	25% ethanol pretreatment followed by virus administration on Day 1
	8	8-10	Ad- β gal	Intravesical	30% ethanol	1.3×10^{11}	30% ethanol pretreatment followed by virus administration on Day 1

For the data in Table 1, the concentration of Ad- β gal virus was 1.3×10^{12} vp/ml as determined by optical density measurements.

Treatment Procedure

1. Animals were anesthetized with isoflurane and a 24 g catheter
5 introduced through the urethra into the bladder.
2. Residual urine was emptied and the bladder was flushed 3 times with 100-150 μ l each of PBS.
3. In test animals, bladders were pretreated for 20 minutes with 0.1 ml of 5, 10, 15, 20, 25 or 30% ethanol solution, respectively, and then rinsed 3 times with 10 100-150 μ l of PBS.
4. Ad- β gal viruses diluted in 0.1 ml of PBS-10% glycerol were administered intravesically into the bladder and retained in the bladder for 45 minutes. A knot was placed around the urethral orifice to prevent leakage of the virus and to prevent the catheter from dislodging.
- 15 5. Treatment was stopped by withdrawing the virus and flushing the bladders 3 times with 100-150 μ l of PBS. If the catheter became clogged, the washing step was avoided so that the virus was flushed out in the urine. However, the use of this procedure may prevent determination of the viral resident time in the bladder.

20 ***Measurement/Determinations***

The clinical condition of the animals was observed before dosing on the day of treatment and the animals were observed daily during the experimental period.

Assessment of β -galactosidase activity

25 Animals were killed 48 hours after treatment. Bladders were filled with 0.1 ml whole organ fixative: 2% Neutral buffered formalin, 2% glutaraldehyde, 2mM MgCl₂, 10 mM PBS, pH 7.4. Bladders were then removed and immersed in whole organ fixative for 1 hr. Thereafter, the bladders were cut open longitudinally, rinsed (2 mM MgCl₂, 0.1% deoxycholate, 0.2% Triton) for 30 24 hours at 4°C, and submerged into X-gal staining solution. Transgene

expression in the luminal epithelium of the longitudinally opened bladders was empirically determined.

Histopathology

Bladders fixed in whole organ fixative were sectioned and stained with
5 hematoxylin-eosin for histologic examination.

Results

Pretreatment of the luminal bladder surface with various concentrations of ethanol (i.e., 15 %, 20 %, 25 %, and 30 wt.%) for 20 minutes resulted in 10 - 20 % transduction. FIGS. 1-4 show transduction of murine bladders after pretreatment
10 with ethanol. FIGS. 1A and 1B are photographs showing a murine bladder after pretreatment with a 15 % ethanol solution followed by infection with Ad-LacZ. FIG. 1A shows the outside surface of the bladder and FIG. 1B shows the luminal bladder surface. FIGS. 1C and 1D are photographs showing a murine bladder after pretreatment with a 20 % ethanol solution followed by infection with Ad-LacZ.
15 FIG. 1C shows the outside surface of the bladder and FIG. 1D shows the luminal bladder surface. FIGS. 1E and 1F are photographs showing a murine bladder after pretreatment with a 25% ethanol solution followed by infection with Ad-LacZ. FIG. 1E shows the outside surface of the bladder and FIG. 1F shows the luminal bladder surface. FIGS. 1G and 1H are photographs showing a murine bladder after
20 pretreatment with a 30 % ethanol solution followed by infection with Ad-LacZ. FIG. 1G shows the outside surface of the bladder and FIG. 1H shows the luminal bladder surface. As can be seen from FIG. 1, higher concentrations of ethanol resulted in greater levels of transduction as measured by staining.

FIG. 2A is a photograph showing a cross section of a murine bladder
25 control (i.e., no pretreatment). FIGS. 2B and 2C are photographs showing the cross section of a murine bladder after pretreatment with a 30 % ethanol solution followed by infection with Ad-LacZ.

FIGS. 3A-3F are photographs showing the cross section of three murine bladders after pretreatment with a 25 % ethanol solution followed by infection with
30 Ad-LacZ. FIGS. 3A and 3B are photographs showing the cross-section of the first

murine bladder, FIGS. 3C and 3D are photographs showing the cross-section of the second murine bladder, and FIGS. 3E and 3F are photographs showing the cross-section of the third murine bladder. FIGS. 3A, 3C and 3E were taken at 40X and FIGS. 3B, 3D and 3F were taken at 100X magnification.

5 FIGS. 4A-4F are photographs showing the cross section of three murine bladders after pretreatment with a 30 % ethanol solution followed by infection with Ad-LacZ. FIGS. 4A and 4B are photographs showing the cross-section of the first murine bladder, FIGS. 4C and 4D are photographs showing the cross-section of the second murine bladder, and FIGS. 4E and 4F are photographs showing the cross-section of the third murine bladder. FIGS. 4A, 4C and 4E were taken at 40X and FIGS. 4B, 4D and 4F were taken at 100X magnification.

10

Effect of Chemical Agent Pretreatment on Adenovirus-Mediated Gene Transfer and Expression in The Bladder Epithelium of Rodent

15 A study was conducted to evaluate the effect of chemical agent pretreatment on adenovirus-mediated gene transfer and expression in the bladder epithelium of rodents.

Test Materials

20 Ad- β gal virus was made at CGI, as a frozen formulation using standard conditions known in the art for freezing and formulation of adenovirus. The vehicle for the virus arm was PBS plus 10% glycerol.

Animals

25 152 female BALB/c mice were used this study. Female animals were chosen because of the ease of urethral cannulation and vesicle instillation. The mice were approximately 10 to 12 weeks on the day of the start of the experiment.

Treatment Regimen

Animals were assigned to each group shown in the following table. The route of administration of the chemical agent and virus was intravesical.

Table 2: Effect of Chemical Agent Pretreatment

Group No.	Animals per group	Test Article	Chemical agent	Virus dose (particles/animal)	Dose Regimen
5	1	2	Vehicle	4% Poloxamer 407 (Pluronic 127)	100 ml of 4% Poloxamer 407 (Pluronic 127) in PBS-10% glycerol on Day 1
	2	6-8	Ad- β gal	4% Poloxamer 407 (Pluronic 127)	4% Poloxamer 407 (Pluronic 127) pretreatment followed by virus administration on Day 1
	3	2	Vehicle	4% Poloxamer 188 (Pluronic F68)	100 ml of 4% Poloxamer 188 (Pluronic F68) in PBS-10% glycerol on Day 1
	4	6-8	Ad- β gal	4% Poloxamer 188 (Pluronic F68)	4% Poloxamer 188 (Pluronic F68) pretreatment following by virus administration on Day 1
	5	2	Vehicle	Lipofectamine 2000	100ml of Lipofectamine 2000 (20mg/ml) in PBS 10% glycerol.
	6	6-8	Ad- β gal	Lipofectamine 2000	1.25mg of Lipofectamine 2000 mixed with virus administration on Day 1
	7	2	Vehicle	3% Benzyl Alcohol	100 μ l of 3% Benzyl Alcohol in PBS -10% glycerol on Day 1
	8	6-8	Ad- β gal	3% Benzyl Alcohol	3% Benzyl Alcohol pretreatment followed by virus administration on Day 1
	9	2	Vehicle	0.2% Oxychlorosene	0.2% Oxychlorosene in PBS-10% glycerol on Day 1

Group No.	Animals per group	Test Article	Chemical agent	Virus dose (particles/animal)	Dose Regimen
5	1	2	Vehicle	4% Poloxamer 407 (Pluronic 127)	- 100 ml of 4% Poloxamer 407 (Pluronic 127) in PBS-10% glycerol on Day 1
	10	6-8	Ad- β gal	0.2% Oxychlorosene	1.3×10^{11} 0.2% Oxychlorosene pretreatment (only wash) followed by virus administration on Day 1
	11	6-8	Ad- β gal	0.2% Oxychlorosene	1.3×10^{11} 0.2% Oxychlorosene pretreatment (5 min) followed by virus administration on Day 1
	12	6-8	Ad- β gal	0.2% Oxychlorosene	1.3×10^{11} 0.2% Oxychlorosene pretreatment (15 min) followed by virus administration on Day 1
	13	2	Vehicle	0.05% Polidocanol	0.05% Polidocanol in PBS-10% glycerol on Day 1
	14	6-8	Ad- β gal	0.05% Polidocanol	1.3×10^{11} 0.05% Polidocanol pretreatment followed by virus administration on Day 1
	15	2	Vehicle	0.1% DC-Chol	0.1% DC-Chol in PBS-10% glycerol on Day 1
	16	6-8	Ad- β gal	0.1% DC-Chol	1.3×10^{11} 0.1% DC-Chol pretreatment followed by virus administration on Day 1
	17	2	Vehicle	In vivo Gene Shuttle (DOTAP + Cholesterol)	4mM solution in PBS
	18	6-8	Ad- β gal	In vivo Gene Shuttle (DOTAP + Cholesterol)	0.65×10^{11} 4mM of In vivo Gene Shuttle mixed with virus. Administration on Day 1. (Dilute 60ml of Lipid with 90ml of water. Then add 150ul of Ad-bgal)
10	19	2	Vehicle	0.5% Polidocanol	0.5% Polidocanol in PBS-10% glycerol on Day 1

Group No.	Animals per group	Test Article	Chemical agent	Virus dose (particles/animal)	Dose Regimen
5	1	Vehicle	4% Poloxamer 407 (Pluronic 127)	-	100 ml of 4% Poloxamer 407 (Pluronic 127) in PBS-10% glycerol on Day 1
	20	6-8	Ad- β gal	0.5×10^{11}	0.5% Polidocanol pretreatment followed by virus administration on Day 1
	21	2	Vehicle	0.4% HPMC 2910	0.4% HPMC 2910 in PBS-10% glycerol on Day 1
	22	6-8	Ad- β gal	0.4×10^{11}	0.8% HPMC 2910 mixed with an equal volume of the virus and then administered on Day 1
	23	2	Vehicle	100 mg/ml Poly-Lysine	100ug/ml Poly-Lysine in PBS-10% glycerol on Day 1
	24	6-8	Ad- β gal	100×10^{11}	200ug/ml Poly-Lysine mixed with an equal volume of the virus and then administered on Day 1
	25	2	Vehicle	0.1% n-dodecyl- β -D glucopyranoside	0.1% n-dodecyl- β -D glucopyranoside in PBS-10% glycerol on Day 1
	26	6-8	Ad- β gal	0.1×10^{11}	0.1% n-dodecyl- β -D glucopyranoside pretreatment followed by virus administration on Day 1
	27	2	Vehicle	0.4% PVA	0.4% PVA in PBS-10% glycerol on Day 1
	28	6-8	Ad- β gal	0.4×10^{11}	0.8% PVA mixed with an equal volume of the virus and then administered on Day 1
10	29	2	Vehicle	0.4% PVP	0.4% PVP in PBS-10% glycerol on Day 1

Group No.	Animals per group	Test Article	Chemical agent	Virus dose (particles/animal)	Dose Regimen
5	1	2	Vehicle	4% Poloxamer 407 (Pluronic 127)	- 100 ml of 4% Poloxamer 407 (Pluronic 127) in PBS-10% glycerol on Day 1
	30	6-8	Ad- β gal	0.4% PVP	0.5×10^{11} 0.8% PVP mixed with an equal volume of the virus and then administered on Day 1
	31	2	Vehicle	0.1% Cholesterol-Cyclodextrin reagent	 0.1% Cholesterol-Cyclodextrin reagent in PBS-10% glycerol on Day 1
	32	6-8	Ad- β gal	0.1% Cholesterol-Cyclodextrin reagent	0.5×10^{11} 0.2% Cholesterol-Cyclodextrin reagent mixed with an equal volume of the virus and then administered on Day 1
	33	2	Vehicle	0.05% n-Dodecyl b-D-Maltoside	 0.05% n-Dodecyl b-D-Maltoside in PBS-10% glycerol on Day 1
	34	6-8	Ad- β gal	0.05% n-Dodecyl b-D-Maltoside	1×10^{11} 0.05% n-Dodecyl b-D-Maltoside pretreatment followed by virus administration on Day 1
	35	2	Vehicle	0.3% Benzyl Alcohol	 100 μ l of 0.3% Benzyl Alcohol in PBS-10% glycerol on Day 1
	36	6-8	Ad- β gal	0.3% Benzyl Alcohol	1×10^{11} 0.3% Benzyl Alcohol pretreatment followed by virus administration on Day 1
	37	2	Vehicle	0.1% Benzyl Alcohol	 100 μ l of 0.1% Benzyl Alcohol in PBS-10% glycerol on Day 1
	38	6-8	Ad- β gal	0.1% Benzyl Alcohol	1×10^{11} 0.1% Benzyl Alcohol pretreatment followed by virus administration on Day 1
10	39	2	Vehicle	0.1% Oxychlorosene	 0.1% Oxychlorosene in PBS-10% glycerol on Day 1

Group No.	Animals per group	Test Article	Chemical agent	Virus dose (particles/animal)	Dose Regimen
5	1	2	Vehicle	4% Poloxamer 407 (Pluronic 127)	- 100 ml of 4% Poloxamer 407 (Pluronic 127) in PBS-10% glycerol on Day 1
	40	6-8	Ad- β gal	0.1% Oxychlorosene	1×10^{11} 0.1% Oxychlorosene pretreatment (5 min) followed by virus administration on Day 1
	41	2	Vehicle	0.4% Oxychlorosene	0.4% Oxychlorosene in PBS-10% glycerol on Day 1
	42	6-8	Ad- β gal	0.4% Oxychlorosene	1×10^{11} 0.4% Oxychlorosene pretreatment (5 min) followed by virus administration on Day 1
	43	2	Vehicle	0.02% Polidocanol	0.02% Polidocanol in PBS-10% glycerol on Day 1
	44	6-8	Ad- β gal	0.02% Polidocanol	1×10^{11} 0.02% Polidocanol pretreatment followed by virus administration on Day 1
	45	2	Vehicle	0.2% Polidocanol	0.2% Polidocanol in PBS-10% glycerol on Day 1
	46	6-8	Ad- β gal	0.2% Polidocanol	1×10^{11} 0.2% Polidocanol pretreatment followed by virus administration on Day 1
	47	2	Vehicle	0.02% n-Dodecyl b-D-Maltoside	0.02% n-Dodecyl b-D-Maltoside in PBS-10% glycerol on Day 1
	48	6-8	Ad- β gal	0.02% n-Dodecyl b-D-Maltoside	1×10^{11} 0.02% n-Dodecyl b-D-Maltoside pretreatment followed by virus administration on Day 1
10	49	2	Vehicle	0.2% n-Dodecyl b-D-Maltoside	0.2% n-Dodecyl b-D-Maltoside in PBS-10% glycerol on Day 1

Group No.	Animals per group	Test Article	Chemical agent	Virus dose (particles/animal)	Dose Regimen
5	1	2	Vehicle	4% Poloxamer 407 (Pluronic 127)	- 100 ml of 4% Poloxamer 407 (Pluronic 127) in PBS-10% glycerol on Day 1
	50	6-8	Ad- β gal	0.2% n-Dodecyl b-D-Maltoside	1×10^{11} 0.2% n-Dodecyl b-D-Maltoside pretreatment followed by virus administration on Day 1
	51	2	Vehicle	0.2% sodium salt of Dodecyl benzenesulfonic acid	0.2% sodium salt of Dodecyl benzenesulfonic acid in PBS-10% glycerol on Day 1
	52	6-8	Ad- β gal	0.2% sodium salt of Dodecyl benzenesulfonic acid	1×10^{11} 0.2% sodium salt of Dodecyl benzenesulfonic acid pretreatment followed by virus administration on Day 1
	53	2	Vehicle	0.1% sodium dodecyl sulphate	0.1% sodium dodecyl sulphate in PBS-10% glycerol on Day 1
	54	6-8	Ad- β gal	0.1% sodium dodecyl sulphate	1×10^{11} 0.1% sodium dodecyl sulphate pretreatment followed by virus administration on Day 1
	55	2	Vehicle	0.1% Tween 20	0.1% Tween 20 in PBS-10% glycerol on Day 1
	56	6-8	Ad- β gal	0.1% Tween 20	1×10^{11} 0.1% Tween 20 pretreatment followed by virus administration on Day 1
	57	2	Vehicle	0.1% Triton X-100	0.1% Triton X-100 in PBS-10% glycerol on Day 1
	58	6-8	Ad- β gal	0.1% Triton X-100	1×10^{11} 0.1% Triton X-100 pretreatment followed by virus administration on Day 1

Group No.	Animals per group	Test Article	Chemical agent	Virus dose (particles/animal)	Dose Regimen
5	1	Vehicle	4% Poloxamer 407 (Pluronic 127)	-	100 ml of 4% Poloxamer 407 (Pluronic 127) in PBS-10% glycerol on Day 1
	59	Vehicle	0.1% Forlan C-24 (PEG Cholesterol)		0.1% Forlan C-24 in PBS-10% glycerol on Day 1
	60	Ad- β gal	0.1% Forlan C-24 (PEG Cholesterol)	1×10^{11}	0.1% Forlan C-24 pretreatment followed by virus administration on Day 1
	61	Vehicle	0.1% Decyl-b-D-Maltoside		0.1% Decyl-b-D-Maltoside in PBS-10% glycerol on Day 1
	62	Ad- β gal	0.1% Decyl-b-D-Maltoside	1×10^{11}	0.1% Decyl-b-D-Maltoside pretreatment followed by virus administration on Day 1
	63	Vehicle	0.1 % 6-Cyclohexylhexyl-b-D-Maltoside		0.1 % 6-Cyclohexylhexyl-b-D-Maltoside in PBS-10% glycerol on Day 1
	64	Ad- β gal	0.1 % 6-Cyclohexylhexyl-b-D-Maltoside	1×10^{11}	0.1 % 6-Cyclohexylhexyl-b-D-Maltoside pretreatment followed by virus administration on Day 1
	65	Vehicle	0.1% Tromboject (Sodium Tetradecyl Sulfate)		0.1% Tromboject in PBS-10% glycerol on Day 1
	66	Ad- β gal	0.1% Tromboject (Sodium Tetradecyl Sulfate)	1×10^{11}	0.1% Tromboject pretreatment followed by virus administration on Day 1
	67	Vehicle	0.1% Phenyl B-D-Glucopyranoside		0.1% Phenyl B-D-Glucopyranoside in PBS-10% glycerol on Day 1

Group No.	Animals per group	Test Article	Chemical agent	Virus dose (particles/animal)	Dose Regimen
1	2	Vehicle	4% Poloxamer 407 (Pluronic 127)	-	100 ml of 4% Poloxamer 407 (Pluronic 127) in PBS-10% glycerol on Day 1
68	6-8	Ad- β gal	0.1% Phenyl B-D-Glucopyranoside	1×10^{11}	0.1% Phenyl B-D-Glucopyranoside pretreatment followed by virus administration on Day 1
69	2	Vehicle	0.1% Sucrose Monolaurate		0.1% Sucrose Monolaurate in PBS-10% glycerol on Day 1
70	6-8	Ad- β gal	0.1% Sucrose Monolaurate	1×10^{11}	0.1% Sucrose Monolaurate pretreatment followed by virus administration on Day 1
71	2	Vehicle	0.1% 1-O-dodecyl-rac-glycerol		0.1% 1-O-dodecyl-rac-glycerol in PBS-10% glycerol on Day 1
5	72	6-8	Ad- β gal	1×10^{11}	0.1% 1-O-dodecyl-rac-glycerol pretreatment followed by virus administration on Day 1

The concentration of Ad- β gal virus for the data in Table 2 was 1.3×10^{12} vp/ml (1st preparation, particle: PFU: 30) and 1×10^{12} vp/ml (2nd preparation, particle: PFU: 30) as determined by optical density measurements.

Treatment Procedure

10 1. The animals were anesthetized with isoflurane and a 24 g catheter was introduced through the urethra into the bladder.

15 2. Residual urine was emptied and the bladder was flushed 3 times with 100 μ l each of PBS.

15 3. Based on the reagent being tested, bladder pretreatment was performed as follows:

Poloxomer 407 procedure: Washed 2 times with 100 μ l each. Retained the 3rd wash for 5 min and gave one additional wash. Performed 3 times PBS wash prior to virus instillation.

5 Poloxomer 188 procedure: Washed 2 times with 100 μ l each. Retained the 3rd wash for 5 minutes and gave one additional wash. Performed 3 times PBS wash prior to virus instillation.

10 Lipofectamine 2000 procedure: Added 5 μ l of stock Lipofectamine (1 mg/ml) to 195 μ l of PBS-10% glycerol. Mixed with an equal volume of Ad- β gal virus and incubated for 15 minutes. Administered 100 μ l of the mixture intravesically and retained in the bladder for 30 minutes.

Benzyl Alcohol procedure: Washed 2 times with 100 μ l each. Retained the 3rd wash for 15 minutes and then gave one additional wash. Performed 3 times PBS wash prior to virus instillation.

15 Oxychlorosene procedure: Washing performed as mentioned in the dose regimen (i.e., 3 washes of 100 μ l each, one wash but retained for 5 min., one wash but retained for 15 min). Performed 3 times PBS wash prior to virus instillation.

Polidocanol procedure: Washed 2 times with 100 μ l each. Retained the 3rd wash for 5 min and then gave one additional wash. Performed 3 times PBS wash prior to virus instillation.

20 DC-Cho procedure: Washed 2 times with 100 μ l each. Retained the 3rd wash for 5 min and then gave one additional wash. Performed 3 times PBS wash prior to virus instillation.

25 0.4% HPMC 2910 procedure: No pretreatment. An equal volume of the virus was mixed with 0.8% solution of HPMC2910 and the mixture was instilled into the bladder for 30 minutes.

100 mg/ml Poly-Lysine procedure: No pretreatment. An equal volume of the virus was mixed with 100 mg/ml solution of Poly-Lysine and the mixture was instilled into the bladder for 30 minutes.

0.4% polyvinyl alcohol (PVA) procedure: No pretreatment. An equal volume of the virus was mixed with 0.8% solution of PVA and the mixture was instilled into the bladder for 30 minutes.

5 n-dodecyl- β -D glucopyranoside procedure: Washed 2 times with 100 μ l each. Retained the 3rd wash for 5 min and then gave one additional wash. Performed 3 times PBS wash prior to virus instillation.

0.4% PVP procedure: No pretreatment. An equal volume of the virus was mixed with 0.8% solution of PVP and the mixture was instilled into the bladder for 30 min.

10 0.1% cholesterol-cyclodextrin reagent procedure: No pretreatment. An equal volume of the virus was mixed with 0.2% solution of Cholesterol-Cyclodextrin and the mixture was instilled into the bladder for 30 minutes.

15 n-dodecyl- β -D-maltoside procedure: Washed 2 times with 100 μ l each. Retained the 3rd wash for 5 min and then gave one additional wash. Performed 3 times PBS wash prior to virus instillation.

Sodium salt of dodecyl benzenesulfonic acid procedure: Washed 2 times with 100 μ l each. Retained the 3rd wash for 5 min and then gave one additional wash. Performed 3 times PBS wash prior to virus instillation.

20 0.1% sodium dodecyl sulphate procedure: Wash 2 times with 100 μ l each. Retained the 3rd wash for 5 min and then gave one additional wash. Performed 3 times PBS wash prior to virus instillation.

0.1% Tween 20 procedure: Washed 2 times with 100 μ l each. Retained the 3rd wash for 5 min and then gave one additional wash. Performed 3 times PBS wash prior to virus instillation.

25 0.1% Triton® X-100 procedure: Washed 2 times with 100 μ l each. Retained the 3rd wash for 5 min and then gave one additional wash. Perform 3 times PBS wash prior to virus instillation.

30 0.1% Forlan C-24 procedure: Washed 2 times with 100 μ l each. Retained the 3rd wash for 5 min and then gave one additional wash. Performed 3 times PBS wash prior to virus instillation.

0.1% decyl- β -D-maltoside procedure: Washed 2 times with 100 μ l each. Retained the 3rd wash for 5 min and then gave one additional wash. Performed 3 times PBS wash prior to virus instillation.

5 0.1 % 6-cyclohexylhexyl- β -D-maltoside procedure: Washed 2 times with 100 μ l each. Retained the 3rd wash for 5 min and then gave one additional wash. Performed 3 times PBS wash prior to virus instillation.

10 0.1% sodium tetradecyl sulfate (Tromboject®, Omega Laboratories Ltd.) procedure: Washed 2 times with 100 μ l each. Retained the 3rd wash for 5 min and then gave one additional wash. Performed 3 times PBS wash prior to virus instillation.

0.1% phenyl- β -D-glucopyranoside procedure: Washed 2 times with 100 μ l each. Retained the 3rd wash for 5 min and then gave one additional wash. Performed 3 times PBS wash prior to virus instillation.

15 0.1% sucrose monolaurate procedure: Washed 2 times with 100 μ l each. Retained the 3rd wash for 5 min and then gave one additional wash. Performed 3 times PBS wash prior to virus instillation.

0.1% 1-O-dodecyl-rac-glycerol procedure: Washed 2 times with 100 μ l each. Retained the 3rd wash for 5 min and then gave one additional wash. Performed 3 times PBS wash prior to virus instillation.

20 25 *In vivo* geneSHUTTLE™ procedure. Mixed 4 mM of *In vivo* geneSHUTTLE™ with virus. Administration on Day 1. Diluted 60 ml of Lipid with 90 ml of water. Then added 150 μ l of Ad- β gal.

4. Virus treatment (45 min) stopped by withdrawing the virus and flushing the bladders 3 times with 100 μ l of PBS.

25 ***Measurement/Determinations***

The clinical condition of the animals were observed before dosing on the day of treatment, and animals were observed daily during the experimental period.

Assessment of β -galactosidase activity

30 Animals were killed 48 hours after treatment. The bladders were filled with 0.1-ml whole organ fixative: 2% Neutral buffered formalin, 2%

glutaraldehyde, 2 mM MgCl₂, 10 mM PBS, pH 7.4. The bladders were then removed and immersed in whole organ fixative for 1 hour. Thereafter, each bladder was cut open longitudinally, rinsed (in 2 mM MgCl₂, 0.1% deoxycholate, 0.2% Triton) for 24 hours at 4 °C, and submerged into X-gal staining solution.

5 Transgene expression in the luminal epithelium of the longitudinally opened bladders was empirically determined.

Histopathology

Bladders fixed in whole organ fixative were sectioned and stained with hematoxylin-eosin for histologic examination.

10 **Results**

The results of the above experiments can be summarized as follows:

Pre-treatment of the bladder with 4% Poloxamer 407 (Pluronic 127) for 5 minutes resulted in < 5% transduction.

15 Treatment of the bladder with a lipofectamine and virus mixture (no pretreatment) resulted in < 5 % transduction.

Treatment of the bladder with an *In vivo* geneSHUTTLE™ and virus mix (no bladder pretreatment) resulted in < 5 % transduction.

20 A pre-treatment of the bladder with 0.1% oxychlorosene for 5 minutes resulted in >90% transduction of the urothelium. The pathologists report indicated mild submucosal edema with intact epithelial layer.

A pre-treatment of the bladder with 0.2% oxychlorosene for 5 minutes resulted in >90% transduction of the urothelium. The pathologists report indicated minimal submucosal edema and perivascular lymphocytes.

25 A pre-treatment of the bladder with 0.2% oxychlorosene for 15 minutes resulted in >90% transduction of Urothelium. The pathologists report indicated focal severe ulceration with suppurtative exudate, hemorrhage and edema in the submucosa.

A pre-treatment of the bladder with 0.4% oxychlorosene for 5 minutes resulted in >90% transduction of Urothelium. The pathologists report indicated moderate submucosal edema with focal large ulcer.

5 A pre-treatment of the bladder with 0.02% polidocanol for 5 minutes resulted in 10-20% transduction of the urothelium. The pathologists report indicated an intact mucosa.

A pre-treatment of the bladder with 0.05% polidocanol for 5 minutes resulted in 30 - 40% transduction of the urothelium. The pathologists report indicated minimal submucosal edema.

10 A pre-treatment of the bladder with 0.2% polidocanol for 5 minutes resulted in 50 - 80% transduction of Urothelium. The pathologists report indicated erosions and focal ulcer as well as mucosal compromise.

15 A pre-treatment of the bladder with 0.02% n-dodecyl β -D-maltoside for 5 minutes resulted in 50 - 80% transduction of the urothelium. The pathologists report indicated no significant lesions.

A pre-treatment of the bladder with 0.05 % n-dodecyl β -D-maltoside for 5 minutes resulted in >90% transduction of the urothelium. The pathologists report indicated no significant lesions.

20 A pre-treatment of the bladder with 0.2 % n-dodecyl β -D-maltoside for 5 minutes resulted in > 90% transduction of the urothelium. The pathologists report indicated erosions, focal ulcer, moderate submucosal edema with mucosal compromise.

A pre-treatment of the bladder with 0.2 % dodecyl benzenesulfonic acid for 5 minutes resulted in 20 - 40 % transduction of the urothelium.

25 As can be seen from the above results, several single compounds and one mixed reagent showed significantly increased transduction as measured by the levels of final blue stain (LacZ). Several other single compounds resulted in enhanced but smaller levels of transduction. An ethanol pre-treatment was used as a reference to validate each chemical tested. Even with an ethanol percentage as high as 30 %, only 10 - 20 % transduction was observed. The "strong responders"

12 Apr 2010

2003299972

WO 2004/060303

PCT/US2003/041379

were those transduction enhancing agents which exhibited significantly better (i.e., 70 - 90 % staining) than the ethanol pre-treatment controls, which exhibited 10 - 20 % staining. The weak responders had significantly less stained area compared to the ethanol control group.

5 The strongest response (i.e., highest level of transduction) was observed following pretreatment of the bladder surface with: 0.02% - 0.5% polidocanol; 0.02 - 0.5% n-dodecyl- β -D-maltoside; 0.1 % 6-cyclohexylhexyl- β -D-maltoside; 0.1% - 0.4% oxychlorosene; 0.2% sodium salt of dodecyl benzenesulfonic acid; and 0.1% sodium dodecyl sulphate.

10 The "weak responders" included 0.1% decyl- β -D-maltoside and 0.1% Triton® X-100.

15 Although not wishing to be bound by theory, the mechanism of action can be hypothesized by analyzing the physical and chemical properties of successful transduction enhancing reagents. The transduction enhancing reagent in general is a surfactant. The surfactant can be ionic or non-ionic. The surfactant preferably has both hydrophilic and lipophilic sections. The hydrophilic portion of the molecule contributes to water solubility while the lipophilic (i.e., hydrophobic) portion helps molecular interactions with lipids. The hydrophilic/lipophilic balance or HLB ratio is an indication of the relative size of each part of the 20 molecule.

Sugar Based Surfactants (Saccharides)


The transduction enhancing agent according to the invention can be a sugar (e.g., a di-, or poly-saccharide) having a lipophilic substituent. The transduction enhancing agent can be any di-, or poly-saccharide having a 25 lipophilic substituent. According to a preferred embodiment of the invention, the transduction enhancing agent is a di-saccharide having a lipophilic substituent. Exemplary di-saccharides include maltose or sucrose. Other di-saccharides having lipophilic substituents, however, can also be used including lactose, isomaltose, trehalose or cellobiose. Monosaccharides are also disclosed as being useful in the methods described herein.

The lipophilic substituent can be linear (e.g., a straight chain n-alkane or alkene) or non-linear (e.g., cyclic or branched chain alkanes or alkenes). The lipophilic substituent can also be an alcanoic acid residue. The length of the lipophilic substituent can be varied to achieve the desired hydrophilic-lipophilic balance. Tests on various maltoside substituted compounds indicated that a sufficient lipophilic length resulted in improved transduction efficacy. For example, both n-dodecyl- β -D-maltoside and 6-cyclohexylhexyl- β -D-maltoside increased transduction significantly. In contrast, n-decyl- β -D-maltoside had only a slight effect on transduction.


Results for bladder pretreatment with n-dodecyl- β -D-maltoside are shown in FIGS. 25-29. FIG. 25A is a photograph showing the luminal surface of a first murine bladder after pretreatment with a 0.02 % n-dodecyl β -D-maltoside solution followed by infection with Ad-LacZ. FIGS. 25B and 25C are photographs showing the cross section of the murine bladder of FIG. 25A. FIG. 25B was taken at 40X and FIG. 25C was taken at 100X magnification. FIG. 26A is a photograph showing the luminal surface of a second murine bladder after pretreatment with a 0.02 % n-dodecyl β -D-maltoside solution followed by infection with Ad-LacZ. FIGS. 26B and 26C are photographs showing the cross section of the murine bladder of FIG. 26A. FIG. 26B was taken at 40X and FIG. 26C was taken at 100X magnification. FIG. 27A is a photograph showing the luminal surface of a first murine bladder after pretreatment with a 0.05 % n-dodecyl β -D-maltoside solution followed by infection with Ad-LacZ. FIGS. 27B and 27C are photographs showing the cross section of the murine bladder of FIG. 27A. FIG. 27B was taken at 40X and FIG. 27C was taken at 100X magnification. FIG. 28A is a photograph showing the luminal surface of a first murine bladder after pretreatment with a 0.05 % n-dodecyl β -D-maltoside solution followed by infection with Ad-LacZ. FIGS. 28B and 28C are photographs showing the cross section of the murine bladder of FIG. 28A. FIG. 28B was taken at 40X and FIG. 28C was taken at 100X magnification. FIG. 29A is a photograph showing the luminal surface of a first murine bladder after pretreatment with a 0.2 % n-dodecyl β -D-maltoside solution

followed by infection with Ad-LacZ. FIGS. 29B and 29C are photographs showing the cross section of the murine bladder of FIG. 29A. FIG. 29B was taken at 40X and FIG. 29C was taken at 100X magnification.

5 The chemical formula for n-dodecyl- β -D-maltoside and n-decyl- β -D-maltoside is given below:




where n is 11 and 9, respectively. The chemical formula for 6-cyclohexylhexyl- β -D-maltoside is:



where n is 6.

10 The transduction experiments demonstrated that a small reduction in the size of the lipophilic side chain (i.e., $\text{CH}_2\text{-CH}_2$) can limit the efficacy of the molecule for transduction enhancement to a great degree. It is important to note that all of the above compounds had good solubility in both water and PBS buffer.

15 Compounds in this class of surfactants having a shorter hydrophilic moiety were also evaluated. The results for n-dodecyl- β -D-glucopyranoside showed little or no enhancement of transduction. The chemical formula for n-dodecyl- β -D-glucopyranoside is:



where n is 11. While not wishing to be bound by theory, the relative sizes of the hydrophilic and lipophilic portions of the molecule appear to influence transduction enhancement. Therefore, shorter chain n-alkyl- β -D-glucopyranosides (e.g., n-hexyl- β -D-glucopyranoside) may exhibit improved transduction.


5 Any mono-, di-, or poly-saccharide having a lipophilic substituent can be used as a transduction enhancing agent according to the invention. Exemplary di-saccharide compounds include sucrose, lactose, maltose, isomaltose, trehalose, and cellobiose. The lipophilic substituent preferably comprises an alkyl or alkenyl group. According to a preferred embodiment of the invention, the lipophilic
10 substituent is an alkanoic acid residue.

Although the β - forms of the mono- and di-saccharides are described above, the α - forms of these and other mono-, di-, or poly-saccharide compounds can also be used according to the invention. Exemplary α -saccharide transduction enhancing agents according to the invention include n-dodecyl- α -D-maltoside, n-
15 hexyl- α -D-glucopyranoside and 6-cyclohexylhexyl- α -D-maltoside. Additionally, either the D- or L- forms of the mono-, di-, or poly-saccharides may be used as transduction enhancing agents according to the invention.


FIGS. 31A-31E are photographs showing the luminal surfaces of murine bladders treated with alkyl maltoside and alkyl maltopyranoside pretreating agents having various length alkyl side chains. FIG. 31A is a photograph of the luminal surface of a murine bladder treated with n-dodecyl- β -D-maltoside (C12 alkyl side chain) prior to infection with Ad-LacZ (10^9 vp). FIG. 31B shows the luminal surface of a murine bladder treated with tridecyl- β -D-maltopyranoside (C13 alkyl side chain) prior to infection. FIG. 31C shows the luminal surface of a murine bladder treated with n-tetradecyl- β -D-maltoside (C14 alkyl side chain) prior to infection. FIG. 31D shows the luminal surface of a murine bladder treated with n-decyl- β -D-maltoside (C10 alkyl side chain) prior to infection. FIG. 31E shows the luminal surface of a murine bladder treated with n-octyl- β -D-maltopyranoside (C8 alkyl side chain) prior to infection.

Ionic Alkyl Surfactants

Ionic alkyl surfactants can also be used as a transduction enhancing compounds according to the invention. Exemplary ionic alkyl surfactants include sodium dodecyl sulfate which has a formula represented by:



Another exemplary ionic surfactant is the sodium salt of dodecylbenzenesulfonic acid which has a chemical formula represented by:



Surfactants of the above type were evaluated and were found to exhibit enhanced transduction comparable to the non-ionic reagents set forth above. These results are shown in FIG. 30 for dodecyl benzenesulfonic acid sodium salt. As can be seen by FIGS. 30A - 30C, dodecyl benzenesulfonic acid sodium salt, enhanced the transduction of Ad-LacZ in murine bladders. FIG. 30A is a photograph showing the luminal surface of a first murine bladder after pretreatment with a 0.2 % sodium salt of dedecyl benzenesulfonic acid solution followed by infection with Ad-LacZ. FIGS. 30B and 30C are photographs showing the cross section of the murine bladder of FIG. 30A. FIG. 30B was taken at 40X and FIG. 30C was taken at 100X magnification.

FIGS. 32A-32C are photographs showing the luminal surfaces of murine bladders treated with sodium alkyl sulfate pretreating agents having various length alkyl chains. FIG. 32A shows the luminal surface of a bladder treated with sodium dodecyl sulfate (SDS) (C12 alkyl side chain) prior to infection with Ad-LacZ (10^9 vp). FIG. 32B shows the luminal surface of a bladder treated with sodium decyl sulfate (C10 alkyl side chain) prior to infection. FIG. 32C shows the luminal

surface of a bladder treated with sodium octyl sulfate (C8 alkyl side chain) prior to infection.

The ionic alkyl surfactants consist of two portions, a hydrophilic portion and a lipophilic portion. The arrangement of these portions of the molecule is similar to the sugar-based enhancing agents described above. According to the invention, compounds similar to those set forth above and having variations in alkyl substitution can also be used.

Alkyl(ether) Alcohols

Also according to the invention, an alkyl ether compound can be used as a transduction enhancing compound. Polidocanol, an alkyl ether having the following chemical formula:




and a total formula of $\sim C_{30}H_{62}O_{10}$, was evaluated. The polidocanol used in the evaluation was sold under the name Thesit®, which is a registered trademark of Desitin-Werk, Carl Klinke GmbH, Hamburg, Germany). There are several other chemical names for polidocanol such as polyethyleneglycoldodecyl ether [9002-92-0], lauryl alcohol, and macrogol lauryl ether.

Results for pretreatment of the bladder surface with various concentrations of polidocanol are shown in FIGS. 19 - 24. Results for pretreatment of the bladder surface with 0.02 % polidocanol are shown in FIGS. 19 and 20. FIG. 19A is a photograph showing the luminal surface of a first murine bladder after pretreatment with a 0.02 % polidocanol solution followed by infection with Ad-LacZ. FIGS. 19B and 19C are photographs showing the cross section of the murine bladder of FIG. 19A. FIG. 19B was taken at 40X and FIG. 19C was taken at 100X magnification. FIG. 20A is a photograph showing the luminal surface of a second murine bladder after pretreatment with a 0.02 % polidocanol solution followed by infection with Ad-LacZ. FIGS. 20B and 20C are photographs showing the cross section of the murine bladder of FIG. 20A. FIG. 20B was taken at 40X and FIG. 20C was taken at 100X magnification.

Results for pretreatment of the bladder surface with 0.05 % polidocanol are shown in FIGS. 21 and 22. FIG. 21A and 21B are photographs showing the outside and luminal surfaces, respectively, of a first murine bladder after pretreatment with a 0.05 % polidocanol solution followed by infection with Ad-LacZ. FIGS. 21C and 21D are photographs showing the cross section of the murine bladder of FIG. 21A. FIG. 21B was taken at 40X and FIG. 21C was taken at 100X magnification. FIG. 22A and 22B are photographs showing the outside and luminal surfaces, respectively, of a second murine bladder after pretreatment with a 0.05 % polidocanol solution followed by infection with Ad-LacZ. FIGS. 22C and 22D are photographs showing the cross section of the murine bladder of FIG. 22A. FIG. 22B was taken at 40X and FIG. 22C was taken at 100X magnification.


Results for pretreatment of the bladder surface with 0.2 % polidocanol are shown in FIGS. 23 and 24. FIG. 23A is a photograph showing the luminal surface of a first murine bladder after pretreatment with a 0.2 % polidocanol solution followed by infection with Ad-LacZ. FIGS. 23B and 23C are photographs showing the cross section of the murine bladder of FIG. 23A. FIG. 23B was taken at 40X and FIG. 23C was taken at 100X magnification. FIG. 24A is a photograph showing the luminal surface of a second murine bladder after pretreatment with a 0.2 % polidocanol solution followed by infection with Ad-LacZ. FIGS. 24B and 24C are photographs showing the cross section of the murine bladder of FIG. 24A. FIG. 24B was taken at 40X and FIG. 24C was taken at 100X magnification.

Triton® X-100, having a general formula of:




wherein x = 10 was also evaluated and was also found to enhance transduction. A similar compound having a cyclohexane ring rather than a benzene ring can also be

used as a transduction enhancing agent according to the invention. This compound has the following chemical structure:



wherein $x=10$. Compounds of the above type wherein x is any positive integer can also be used according to the invention.

5 Similar alkyl(ether) compounds having the general structure of:



are also commercially available. The trade name for these compounds is "Brij".

The compound shown above is designated "Brij 56". Brij 56 has the chemical formula $C_{20}H_{42}O_5$. Another commercially available compound, "Brij 58", has the chemical formula $C_{56}H_{114}O_{21}$.

10 Any of the above mentioned alkyl(ether) compounds can be used as transduction enhancing agents according to the invention.

Sodium Oxychlorosene

15 A composition comprising a sodium salt of dodecylbenzenesulfonic acid and hypochlorous acid (i.e., sodium oxychlorosene) at a pH of about 6.5 to 6.9 was evaluated. The sodium oxychlorosene used in these evaluations was sold under the name Clorpactin WCS-90 (manufactured by Guardian Labs and sold by Cardinal Health). Sodium oxychlorosene has been used to treat urinary tract infections and in abdominal and plastic surgery.

20 Results for pretreatment of the bladder surface with sodium oxychlorosene are shown in FIGS. 8-18. FIGS. 8A - 8N are photographs showing seven murine bladders after pretreatment with a 0.2 % oxychlorosene solution for 5 minutes followed by infection with Ad-LacZ. FIGS. 8A and 8B show the outside and luminal surfaces, respectively, of the first bladder, FIGS. 8C and 8D show the outside and luminal surfaces, respectively, of the second bladder, FIGS. 8E and 8F

show the outside and luminal surfaces, respectively, of the third bladder, FIGS. 8G and 8H show the outside and luminal surfaces, respectively, of the fourth bladder, FIGS. 8I and 8J show the outside and luminal surfaces, respectively, of the fifth bladder, FIGS. 8K and 8L show the outside and luminal surfaces, respectively, of the sixth bladder, and FIGS. 8M and 8N show the outside and luminal surfaces, respectively, of the seventh bladder.

FIGS. 9A-9N are photographs showing seven murine bladders after pretreatment with a 0.2 % oxychlorosene solution for 15 minutes followed by infection with Ad-LacZ. FIGS. 9A and 9B show the outside and luminal surfaces, respectively, of the first bladder, FIGS. 9C and 9D show the outside and luminal surfaces, respectively, of the second bladder, FIGS. 9E and 9F show the outside and luminal surfaces, respectively, of the third bladder, FIGS. 9G and 9H show the outside and luminal surfaces, respectively, of the fourth bladder, FIGS. 9I and 9J show the outside and luminal surfaces, respectively, of the fifth bladder, FIGS. 9K and 9L show the outside and luminal surfaces, respectively, of the sixth bladder, and FIGS. 9M and 9N show the outside and luminal surfaces, respectively, of the seventh bladder.

FIGS. 10A and 10B are photographs showing the cross section of the murine bladders of FIGS. 8C and 8I, respectively. FIGS. 11A and 11B are photographs showing the cross section of the murine bladders of FIGS. 9C and 9I, respectively.

FIGS. 12A-12F are photographs showing the cross section of three murine bladders after pretreatment with a 0.2 % oxychlorosene solution for 5 minutes followed by infection with Ad-LacZ. FIGS. 12A and 12B are photographs showing the cross-section of the first murine bladder, FIGS. 12C and 12D are photographs showing the cross-section of the second murine bladder, and FIGS. 12E and 12F are photographs showing the cross-section of the third murine bladder. FIGS. 12A, 12C and 12E were taken at 40X and FIGS. 12B, 12D and 12F were taken at 100X magnification.

FIGS. 13A-13F are photographs showing the cross section of three murine bladders after pretreatment with a 0.2 % oxychlorosene solution for 15 minutes followed by infection with Ad-LacZ. FIGS. 13A and 13B are photographs showing the cross-section of the first murine bladder, FIGS. 13C and 13D are 5 photographs showing the cross-section of the second murine bladder, and FIGS. 13E and 13F are photographs showing the cross-section of the third murine bladder. FIGS. 13A, 13C and 13E were taken at 40X and FIGS. 13B, 13D and 13F were taken at 100X magnification.

FIG. 14A is a photograph showing the luminal surface of a murine bladder 10 after pretreatment with a 0.1 % oxychlorosene solution followed by infection with Ad-LacZ. FIGS. 14B and 14C are photographs showing the cross section of the murine bladder of FIG. 14A. FIG. 14B was taken at 40X and FIG. 14C was taken at 100X magnification;

FIG. 15A is a photograph showing the luminal surface of a first murine 15 bladder after pretreatment with a 0.2 % oxychlorosene solution followed by infection with Ad-LacZ. FIGS. 15B and 15C are photographs showing the cross section of the murine bladder of FIG. 15A. FIG. 15B was taken at 40X and FIG. 15C was taken at 100X magnification.

FIG. 16A is a photograph showing the luminal surface of a second murine 20 bladder after pretreatment with a 0.2 % oxychlorosene solution followed by infection with Ad-LacZ. FIGS. 16B and 16C are photographs showing the cross section of the murine bladder of FIG. 16A. FIG. 16B was taken at 40X and FIG. 16C was taken at 100X magnification.


FIG. 17A is a photograph showing the luminal surface of a first murine 25 bladder after pretreatment with a 0.4 % oxychlorosene solution followed by infection with Ad-LacZ. FIGS. 17B and 17C are photographs showing the cross section of the murine bladder of FIG. 17A. FIG. 17B was taken at 40X and FIG. 17C was taken at 100X magnification.

FIG. 18A is a photograph showing the luminal surface of a second murine 30 bladder after pretreatment with a 0.4 % oxychlorosene solution followed by

infection with Ad-LacZ. FIGS. 18B and 18C are photographs showing the cross section of the murine bladder of FIG. 18A. FIG. 18B was taken at 40X and FIG. 18C was taken at 100X magnification.

Polymers with Alternating Hydrophilic and Lipophilic Units

5 Polymeric compounds comprising repeating sequences of alternating or identical monomers were also tested. One such compound tested was Poloxamer 407 (Pluronic 127) having a structure represented by the following formula:




10 Poloxamers polymers come in a wide range of HLB values. Both of the compounds tested, however, had only a minimal effect on the transduction of adenovirus. While not wishing to be bound by theory, it is believed that compounds having separated, longer hydrophilic and lipophilic chains are more effective at enhancing transduction of the bladder epithelium.


Additional Transduction Enhancing Compounds

15 Additional compounds can also be used as transduction enhancing agents according to the invention.

These compounds include ω -undecylenyl- β -D-maltopyranoside, which has a structure represented by:




20 Sugar based thiolic compounds such as alkyl- β -D-thioglucopyranosides having a general structure represented by:




may also be employed.

Additionally, alkyl- β -D-thiomaltopyranosides having a general structure represented by:




5 may also be used as transduction enhancing compounds according to the invention.

Further, compounds having a positive charge such as



can also be used.

10 Additionally, compounds wherein the lipophilic and hydrophilic parts are connected via a carboxylic bond can also be employed. An exemplary compound of this type is 6-O-methyl-n-heptylcarboxyl- α -D-glucopyranoside:




Sugar based compounds having alkyl groups with side groups or other modifications may also be used. Exemplary compounds of this type include 2-propyl-1-pentyl- β -D-maltopyranoside having a structure represented by:

12 Apr 2010


2003299972

WO 2004/060303


PCT/US2003/041379



Sarcosine compounds may also be used as transduction enhancing agents according to the invention. Exemplary sarcosine compounds include sodium alkyl sarcosine having a structure represented by:



Various substituted sugars can also be used as transduction enhancing compounds. An exemplary substituted sugar which can be used as a transduction enhancing compound is a sucrose mono alkyl ester having a chemical structure represented by:



Exemplary compounds of this type include compounds wherein n=10 (i.e., sucrose monolaurate).

Also according to the present invention, methods of treating the luminal surface of the bladder are provided. According to a preferred embodiment of the invention, the bladder is treated by instillation using bladder catheterization. According to this embodiment, any urine in the bladder is first removed and the bladder is optionally washed with a buffer (e.g., PBS). A composition comprising the transduction enhancing agent is then applied to the luminal surface of the bladder (e.g., by instillation). The transduction enhancing solution may be

incubated for some specified time or drained immediately. Multiple treatments with the composition comprising the transduction enhancing agent can be performed. After treatment with the transduction enhancing agent, the luminal surface of the bladder may be washed with a buffer (e.g., PBS). A solution comprising the adenovirus can then be introduced into the bladder (e.g., by instillation). The solution comprising the adenovirus can be removed immediately or, alternatively, the solution can be allowed to incubate for a certain amount of time. After treatment with the adenovirus, the bladder surface can again be washed with a buffer solution (e.g., PBS). According to a preferred embodiment of the invention, about 50 to about 500 ml of the transduction enhancing composition is delivered to the bladder by instillation for each treatment.

Alternatively, a composition comprising the transduction enhancing agent and the adenovirus can be used to treat the luminal bladder surface. According to this embodiment of the invention, any urine in the bladder is first removed and the bladder is then optionally washed with a buffer (e.g., PBS). A composition comprising the transduction enhancing agent and the adenovirus is then applied to the luminal surface of the bladder. The solution may be incubated for some specified time or drained immediately. After treatment, the luminal surface of the bladder may again be washed with a buffer (e.g., PBS).

Although phosphate buffered saline (PBS) is the preferred buffer, any other pharmaceutical buffer can be used according to the invention. Exemplary buffers include sodium phosphate/sodium sulfate, Tris buffer, glycine buffer, sterile water and other buffers known in the art, including those described by Good, et al., *Biochemistry* 5, 467 (1966). The pH of the buffer can be in the range of 6.4 to 8.4, preferably 7 to 7.5, and most preferably 7.2 to 7.4.

The composition comprising the transduction enhancing agent according to the invention preferably also comprises an oxidizing agent. Exemplary oxidizing agents include, but are not limited to, chlorite compounds, hypochlorous acid, hydrogen peroxide, and peroxyacetic acid. According to a preferred embodiment

of the invention, any of the single compound transduction enhancing agents can be combined with an oxidizing agent and used as a transduction enhancing agent.

As set forth above, the viral gene therapy vehicle can be an oncolytic virus, for example an oncolytic adenovirus exemplified herein by CG8840. The 5 adenovirus composition can further comprise a chemotherapeutic agent such as Docetaxel. The adenovirus composition preferably comprises from about 1×10^{11} to about 1×10^{14} viral particles.

Various additional studies were conducted and are described below. In 10 these studies, all percent values that are presented are weight percent values unless otherwise indicated.

Effects of Adenovirus Formulation with Different Concentrations of Dodecyl- β -D-Maltoside on the Infectivity of Mice Bladder Urothelium

Species: Female Balb/c Mouse (Taconic Laboratory) - 2/group

Study Design: To test the effect of formulating Ad- β gal virus with different 15 concentrations of Dodecyl- β -D-Maltoside and the resultant infection of mice bladder urothelium

Dose/Route (Viral Particles #/dose):

1x 10^{10} vp/dose of Ad.CMV.LacZ (Lot# 1351.122)
0.4 %, 0.2 %, 0.1 %, and 0.05 % of n-Dodecyl- β -D-Maltoside (Lot# 20 100K5308).

An equal volume of 2x DDM and 2x Ad.CMV.LacZ was mixed together immediately before instillation into the bladder. 100 μ l of the mixture was instilled into the bladder for 10 min, 20 min, and 45 min.

Endpoints: Bladders were harvested 48 hrs post virus infection with 0.1 ml whole 25 organ fixative (2% Neutral buffered formalin, 2% glutaraldehyde, 2 mM MgCl₂, 10 mM PBS, pH 7.4).

Results: Formulating Ad- β gal virus with different concentrations of Dodecyl- β -D-Maltoside resulted in a linear Adenovirus transduction rate (0.1 % > 0.05 % > 0.025 %). For the 20 min. instillation, 0.1% DDM formulated with Ad- β gal virus 30 resulted in about 80% gene expression in bladder, while 0.05% DDM resulted in

about 40 % gene expression. But with 45 min. instillation, all animals with 0.05 % - 0.2 % DDM with Ad- β gal virus had 100 % gene expression in mice bladder. A 10 min. instillation for this formulation method, however, did not achieve an acceptable transduction rate. It was also found that gene transduction could be 5 achieved with a 10 min. virus instillation after DDM pretreatment.

This study illustrates that DDM can be formulated with Ad- β gal virus in mice bladder model. Further, with a DDM pretreatment, the time for virus instillation can be decreased to 10 min. from 45 min.

Effects of Different Diluents on the Infectivity of Mice Bladder Urothelium by 10 Adenovirus

Species: Female Balb/c Mouse (Taconic Laboratory) - 2/group

Study Design: To test the effects of different diluents on Adenovirus infectivity of mice urothelium followed DDM pretreatment (QQ5minQ). The virus would be diluted 100 fold with the diluents prior to instillation into mice bladder for 45 min.

15 Dose/Route:

1x10⁹ vp/dose of Ad.CMV.LacZ (Lot #1351.122)

Dodecyl- β -D-Maltoside (Lot #100K5308).

Diluents (A): 0.9% Sodium Chloride Injection Solution (Baxter Lot# 1A1322); (B): 2.5% Dextrose and 0.45% Sodium Chloride Injection Solution 20 (Baxter Lot# C529040); and (C): Plasma-lyte A Injection Solution pH 7.4 (Baxter Lot# C558106); and ARCA buffer.

Endpoints: Bladders were harvested 48 hrs post virus infection with 0.1 ml whole organ fixative (2 % Neutral buffered formalin, 2 % glutaraldehyde, 2 mM MgCl₂, 10 mM PBS, pH 7.4).

25 Results: There were no significant differences in Ad- β gal gene expression levels between mice bladder receiving virus diluted with different diluents. All the animals had >90 % in Ad- β gal gene expression in mice bladder.

Adenovirus Dose Titration with Different Chemical Agents Pretreatment on SD Rat Bladder Epithelium

Species: Female Sprague Dawley Rat (Taconic Laboratory) - 2/group

Study Design: To test the virus infectivity of rat bladder epithelium with different doses of Adenovirus following the pretreatment with SDS or DDM. This study 5 also explored relationship between bladder volume and residual of SDS or DDM for adenovirus infectivity.

Dose/Route:

4x10⁹ and 4x10¹⁰ vp/dose of Ad.CMV.LacZ (Lot# 1351.122)

10 0.1% Dodecyl- β -D-Maltoside (Lot#100K5308)

0.1% SDS (Integra Lot# 836011 and Lot# BK14J11)

400 μ l of SDS or DDM was instilled into bladder (QQ5minQ) followed by six PBS washes, then Adenovirus for 15 min.

Endpoints: Bladders were harvested 48 hrs post virus infection with 0.2 ml whole 15 organ fixative (2 % Neutral buffered formalin, 2 % glutaraldehyde, 2 mM MgCl₂, 10 mM PBS, pH 7.4).

Results: There were no significant differences in Ad- β gal gene expression levels between rat bladders pretreated with different lot of SDS and DDM. Rat bladders infected with 4x10¹⁰ vp adenovirus achieved > 90 % Ad- β gal gene expression 20 levels whereas rat bladders infected with 4x10⁹ vp adenovirus had Ad- β gal gene expression levels range from 30% to 50%. It was found that rat bladder needed 10 times more adenovirus to achieve similar Ad- β gal gene expression levels compared with mouse bladder. SDS and DDM pretreatment were both effective to remove GAG layer of bladder epithelium.

25 ***Efficacy of Dodecyl- β -D-Maltoside as a Pretreatment Agent Prior to Adenovirus Infection of Mice Bladder Urothelium***

Species: Female Balb/c Mouse (Taconic Laboratory) - 2/group

Study Design: To test DDM from two different suppliers as pretreatment agents to enhance the adenovirus infection of mice bladder urothelium in a large group of animals.

Dose/Route:

5 1x10¹⁰ vp/dose of Ad.CMV.LacZ (Lot #1351.122)
 Dodecyl- β -D-Maltoside (Lot # 018H7250 and Lot # P21/39/092)
 100 μ l of DDM was instilled into bladder (QQ5minQ) followed by three
 PBS washes, then Adenovirus for 15 min.

10 **Endpoints:** Bladders were harvested 48 hrs post virus infection with 50 μ l whole
 organ fixative (2 % Neutral buffered formalin, 2 % glutaraldehyde, 2 mM MgCl₂,
 10 mM PBS, pH 7.4).

15 **Results:** There were no significant differences in Ad- β gal gene expression levels
 between mice bladder pretreated with these two different lots of DDM. In each
 case, >90 % Ad- β gal expression was achieved. Therefore, DDM from either
 manufacturer is a good candidate for a chemical enhancer for adenovirus infection
 in mice bladder.

***Efficacy of Dodecyl- β -D-Maltoside as Chemical Enhancer Prior to Adenovirus
Infection of SW780+Luc Orthotopic Bladder Tumor Model in Mice***

20 **Species:** Female NCR nu/nu Mouse (Taconic Laboratory) - 2/group
 Study Design: To show DDM pretreatments enhance Ad.Lac Z infectivity in mice
 bladder urothelium. To further confirm the enhancer effect on orthotopic tumors,
 two mice bearing orthotopic SW780 bladder tumors were pretreated with or
 without DDM (QQ5minQ) followed by 15 min Ad.Lac Z instillation. The Ad.Lac
 Z gene expression levels were checked in these tumor cells 4 days post Ad.Lac Z
 infection.

Dose/Route:

25 1x10¹⁰ vp/dose. Ad.CMV.LacZ Lot# 1351.122.
 Dodecyl- β -D-Maltoside (Lot#018H7250).
 100 μ l of DDM was instilled into bladder (QQ5minQ) followed by three
 PBS washes, then Adenovirus for 15 min.

Endpoints: Bladders were harvested 96 hrs post virus infection with 50 μ l whole organ fixative (2 % Neutral buffered formalin, 2 % glutaraldehyde, 2 mM MgCl₂, 10 mM PBS, pH 7.4).

5 **Results:** There was a significant difference in Ad- β gal gene expression levels between mice bladders pretreated with DDM and control animals. Without DDM pretreatment, there was very low Ad- β gal gene expression levels in bladder epithelium cells and tumor cells. With DDM pretreatment, nearly 100 % of the epithelium cells were transduced with Ad- β gal gene in bladder tumors except those dead necrotic tumor cells. It was concluded that DDM pretreatment enhances 10 Adenovirus infection in orthotopic tumor cells.

Testing of DDM and SDS Subgroup Compounds Containing Different Lengths of Alkyl Side Chain and Different Types of Sugar Molecule as Pretreatment Agents Prior to Adenovirus Infection of Mouse Bladder Urothelium

15 **Species:** Female Balb/c Mouse (Taconic Laboratory) - 3-2/group
Study Design: Several compounds belonging to the Dodecyl- β -D-Maltoside (DDM) and Sodium Dodecyl Sulfate (SDS) subgroups containing different lengths of alkyl side chain and different sugar molecules were tested as pretreatment agents to enhance the adenovirus infection of mouse bladder epithelium. All compounds were dissolved in PBS at 0.1 % concentration.

20 **Dose/Route:**

1x10⁹ vp/dose. Ad.CMV.LacZ (Lot #1351.122)
0.1% Dodecyl- β -D-Maltoside (Lot #P21/39/092) and 0.1% SDS (Lot #101K0036) were the positive controls for this study.

25 100 μ l of Ad- β gal virus was instilled into bladder via intravesicle administration for 15 min followed different chemicals pretreatment (QQ5minQ).

Endpoints: Bladders were harvested 48 hrs post virus infection with 50 μ l whole organ fixative (2 % Neutral buffered formalin, 2 % glutaraldehyde, 2 mM MgCl₂, 10 mM PBS, pH 7.4).

Results: For the DDM subgroup compounds, compounds with alkyl side chain lengths longer than C12 had the best enhancer ability. DDM subgroup compounds having C8, C10, C12, C13 and C14 alkyl side chains were evaluated. For the SDS subgroup compounds, compounds with alkyl side chain lengths shorter than C12 had very low Ad- β gal gene expression levels. SDS subgroup compounds having C8, C10 and C12 alkyl side chains were evaluated.

5 The type of sugar molecule did not appear to have a significant effect on the efficacy of these compounds as pretreatment enhancers with the exception of sucrose monolaurate. While not wishing to be bound by theory, we believe that the
10 disaccharide chain could enhance adenovirus infectivity based on currently available data.

Pilot Efficacy Study: CG8840 Treatment with SW780+Luc Orthotopic Bladder Tumor Model in Mice

Species: Female NCR nu/nu Mouse (Taconic or Simonsen Laboratory) - 6/group
15 for CG8840 and 3/group for CG7870

Study Design: To test the efficacy of bladder specific oncolytic virus CG8840 alone with prostate specific oncolytic virus CG7870. Two treatment regimens were used for CG8840: 1×10^{10} and 1×10^8 vp/dose. One treatment regimen was used for CG7870: 1×10^{10} vp/dose. One dose of virus would be delivered into
20 bladder weekly for the consecutive three weeks.

Dose/Route:
1 million SW780+Luc cells Clone #19 (P4)
CG8840 Lot# 1408.190; CG7870 (Lot # 38.145)
0.1% Dodecyl- β -D-Maltoside (Lot #018H7250).
25 15 mg/ml Luciferin (Xenogen cat# XR-1001) substrate solution was made in PBS filtered with 0.2 μ M filters.

120 μ l of 1×10^7 cell/ml SW780+Luc cells were aliquot into each tube and kept in ice before instillation. One aliquot for each mice bladder.

Endpoints: Live image mice bladder was performed weekly for 10 weeks. H & E stain and Human Cytokeratin Stain were performed on those available bladder and kidney samples.

Results: There were significant differences in reducing tumor volumes between 5 CG8840 (1×10^{10} vp/dose) treated mice and control animals (both CG7870 and no virus treated groups). Three out of six mice treated with 1×10^{10} vp/dose CG8840 had completed tumor regression after second dose instillation and kept tumor free until the end of the study (week 10). Human cytokeratin stain showed there were no tumor cells in those mouse bladders. Efficacy for 1×10^8 vp/dose of CG8840 10 was not significant, there was a one out of five mouse had incomplete tumor regression on week 5 and kept tumors at bay to the end. Tumor metastasis to kidney is a significant threat to tumor bearing mice survival. Any mice with kidney metastasis would soon die even if they were free of bladder tumors.

CG8840 Treatment with SW780+Luc Orthotopic Bladder Tumor Model in Mice

15 **Species:** Female NCR nu/nu Mouse (Taconic Laboratory) - 10/group

Study Design: This study was designed to observe the efficacy of bladder specific oncolytic virus CG8840 treatment modality for bladder tumors. CG8840 virus was instilled into the bladder via intravesical administration for 15 min and 30 min, respectively. To reduced kidney tumor metastasis, two different DDM 20 pretreatment procedures were tested during SW780 tumor cell implanting: (1) 0.1% DDM QQ5minQ; and (2) 0.1% DDM Q10min.

Dose/Route:

1 million SW780+Luc cells Clone #19 (P4).

CG8840 Lot# 1408.190. 0.1% Dodecyl- β -D-Maltoside (Lot #018H7250).

25 15 mg/ml Luciferin (Xenogen cat# XR-1001) substrate solution was made in PBS filtered with 0.2- μ M filters.

90 μ l of 1.1×10^7 cell/ml SW780+Luc cells were aliquot into each tube and kept in ice before instillation. One aliquot for each mice bladder.

Endpoints: Live imaging of the mice bladders was performed weekly for 8

weeks. H & E stain and Human Cytokeratin Stain were performed on those available bladder and kidney samples.

Results: There were significant difference in reducing tumor volumes between CG8840 (15 min. and 30 min. virus treatment) treated mice and control animals.

5 In particular, seven out of nine mice with 15 min. virus treatment showed significant tumor volume regression after first virus treatment. Five of them were tumor free till the end of the study. The CG8840 treatment with three doses of 1×10^{10} vp/dose injected in three consecutive weeks proved very effective to eradicate orthotopic SW780 tumors in mouse bladder. However, longer virus 10 instillation times (i.e., in excess of 15 min.) do not appear to increase virus copy numbers within tumor cells.

For SW780 tumor cell implantation, 0.1% DDM pretreatment with Q10 min. washes, less kidney tumor metastasis was observed in mice with orthotopic tumors.

15 Varius additional studies were conducted to determine adenovirus compatibility with various reagents. These studies are described below.

Study #1 - Compatibility of Ad5-LacZ with Ethanol and Urine

In this study, each sample was incubated at 37 °C for one hour before the plaque assay started. The data for this study are shown below in Table 3.

20

Table 3: Adenovirus stability after incubation (EtOH, urine)

25

	Titer	Average	Stdev.	Ratio
Sample Name	vp/mL	pfu/mL		vp/pfu
Ad5-Lac Z in ARCA	1.30E+12	5.85E+10	1.49E+10	22.23
Ad5-Lac Z in ARCA 40% EtOH	7.80E+11	6.36E+07	1.68E+07	12255.34
Ad5-Lac Z in ARCA 5% EtOH	1.24E+12	5.07E+10	0.00E+00	24.47
Ad5-Lac Z in ARCA 1:100 Urine	1.30E+10	6.26E+08	2.55E+08	20.75
Ad5-Lac Z -80°C	1.30E+12	5.90E+10	9.28E+09	22.04
R-06-80 1 Hr. Hold	6.00E+11	2.34E+10	2.76E+09	25.65
R-06-81	6.00E+11	3.12E+10	8.27E+09	19.24

This data indicates that Ad-LacZ does not lose its activity after incubation with urine, 5% ethanol, or ARCA at biological temperature. However, 40 % ethanol inactivated most of the virus.

Study #2: Compatibility of Ad5-LacZ with Ethanol

5 For this study, each sample was incubated at 37 °C before the plaque assay started. The data for this study are shown below in Table 4.

Table 4: Adenovirus Stability after Incubation (EtOH, PBS)

	Titer	Average	St. dev.	Ratio
Sample Name	vp/mL	pfu/mL		vp/pfu
Ad 5 Lac Z	1.30E+12	4.34E+10	7.58E+09	30
Ad 5 Lac Z in PBS	1.30E+11	5.43E+09	4.26E+08	24
PBS/10 % EtOH	1.30E+11	3.72E+09	4.26E+08	35
PBS/20 % EtOH	1.30E+11	1.81E+09	2.84E+08	72
PBS/30 % EtOH	1.30E+11	<1.1E+5 pfu/mL		
1230-054	1.00E+11	9.55E+08	2.13E+08	105
R-06-80	6.00E+11	1.90E+10	6.20E+09	32

The above results indicate that higher concentrations of ethanol (i.e., $\geq 10\%$) will result in partial to complete inactivation of adenovirus.

Study #3 - Compatibility of Adenovirus with Selected Enhancers

For this study, each sample was incubated at 37 °C or 25 °C before the plaque assay started. The data for this study are shown below in Table 5.

Table 5: Adenovirus Stability after Incubation with Selected Enhancer Solutions

Solution	Temp	Incub.	Titer	Average	St. Dev.	Ratio
		Time	vp/mL	pfu/mL		vp/pfu
None	5°C	none	4.23E+11	1.95E+10	0.00E+00	22
Oxychlorosene	37°C	1 hour	2.12E+11	8.82E+05	1.56E+05	240287
Dodecyl Maltoside	37°C	1 hour	2.12E+11	1.36E+10	1.38E+09	16
Polidocanol	37°C	1 hour	2.12E+11	1.22E+10	2.07E+09	17
Oxychlorosene	25°C	2 hours	2.12E+11	2.18E+08	0.00E+00	974
Dodecyl Maltoside	25°C	2 hours	2.12E+11	1.32E+10	6.89E+08	16
Polidocanol	25°C	2 hours	2.12E+11	1.02E+10	4.82E+09	21
none	-70°C	none	6.00E+11	2.76E+09	2.13E+08	21.7

As can be seen from the above data, dodecyl maltoside and polidocanol are compatible with the adenovirus under the experimental conditions while oxychlorosene can inactivate the virus by increase in temperature and time of incubation.

5 ***Study #4 - Degradation of Adenovirus by Sodium Dodecyl Sulfate (SDS)***

A series of experiments were preformed on samples of adenovirus incubated at 37 °C for 15 - 30 minutes in various concentrations of SDS. The resulting material was examined by anion exchange chromatography. It was confirmed that concentrations of SDS above or equal to 0.025 % SDS will rapidly 10 degrade the virus. SDS at 0.0125 % did not reduce the particle quality or quantity by AEX method after 30 minutes of incubation.

Study #5 - Degradation of Adenovirus by Sodium Dodecyl Sulfate (SDS)

In this study, adenovirus (Ad-LacZ) preparations (1.0×10^{12} vp/ml) were mixed with solutions of SDS or DDM to obtain a mixture of adenovirus and each 15 of these surfactants. Final concentrations of SDS or DDM were 0.1 % and the virus had a 5.0×10^{11} vp/ml as the result of mixing. These samples were incubated at 25 °C or 37 °C for one hour before freezing. They were sent to assay services at for plaque assay analysis. The results for this study are shown below in Table 6.

Table 6 - Adenovirus Stability after Incubation with 0.1% SDS or 0.1% DDM

20 ***Solutions***

Sample ID	Replicate	Titer	Mean Titer PFU/mL
Ad-LacZ 1351-122	1	3.70E+10	4.85E+10
	2	6.00E+10	
Ad-LacZ ARCA 1 Hr 25 °C	1	2.05E+10	2.05E+10
Ad-LacZ ARCA 1 Hr 37 °C	1	2.15E+10	2.15E+10
Ad-LacZ DDM 1 Hr 25 °C	1	3.25E+10	3.25E+10
Ad-LacZ DDM 1 Hr 37 °C	1	3.55E+10	3.55E+10
Ad-LacZ SDS 1 Hr 25 °C	1	no activity	no activity
Ad-LacZ SDS 1 Hr 37 °C	1	no activity	no activity

This experiment confirmed that a relatively short exposure of adenovirus at elevated temperatures to SDS solutions will inactivate the virus. However, the DDM solution had no adverse effects on adenovirus.

The following table (Table 7) summarizes the transduction efficacy of exemplary pretreatment agents. In Table 7, transduction efficacy is defined as follows: "0" means 0 - 10% transduction efficacy; "+" means 10 - 25 % transduction efficacy; "++" means 25 - 50 % transduction efficacy; "+++" means 50 - 75 % transduction efficacy; and "++++" means >75 % transduction efficacy.

Table 7: Transduction Efficacy of Exemplary Pretreatment Agents

	Pretreatment Agent	Transduction Efficacy
10	Alkyl disaccharides	
	n-Dodecyl-β-D-Maltoside (C12)	++++
	n-Dodecyl-α-D-Maltoside (C12)	++++
	Sucrose monolaurate (C12)	++++
15	6-Cyclohexylhexyl-β-D-Maltoside	++++
	n-Tridecyl-β-D-Maltoside (C13)	+++
	n-Tetradecyl-β-D-Maltoside (C14)	++
	n-Decyl-β-D-Maltoside (C10)	+
	n-Octyl-β-D-Maltoside (C8)	(0)
20	Alkyl sulfate (ionic Alkyl)	
	Sodium dodecyl sulfate (C12)	++++
	Sodium decyl sulfate (C10)	+
	Sodium octyl sulfate (C8)	(0)
	Sodium tetradecyl sulfate (C14)	(0)
25	Na salt of dodecyl benzenesulfonic acid	+
	Alkyl (ether) alcohols	
	Polidocanol	++
	Polymeric surfactants	
	Triton X-100	+
30	Poloxamers F68, F127	(0)
	Tween 20, Tween 80	(0)

While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be appreciated by one skilled in the art from reading this disclosure that various

2003299972 12 Apr 2010

WO 2004/060303

PCT/US2003/041379

changes in form and detail can be made without departing from the true scope of the invention.


In this specification where reference has been made to patent specifications, other external documents, or other sources of information, this is generally for the purpose of providing a context for discussing the features of the invention. Unless specifically stated otherwise, reference to such external documents is not to be construed as an admission that such documents, or such sources of information, in any jurisdiction, are prior art, or form part of the common general knowledge in the art.

12 Apr 2010


2003299972

WHAT WE CLAIM IS:

1. A method for treating cancer of the bladder comprising:
contacting the luminal surface of the bladder with a pretreatment composition comprising a transduction enhancing agent, either together with a composition comprising an oncolytic virus or before contacting the luminal surface of the bladder with a composition comprising an oncolytic virus;
wherein the transduction enhancing agent is a disaccharide having a lipophilic substituent and wherein the disaccharide is selected from the group consisting of sucrose, lactose, maltose, isomaltose, trehalose and cellobiose.
2. The method of Claim 1, wherein the transduction enhancing agent has the following general formula (I):



wherein X is a sulfur or oxygen atom, each R² is independently hydrogen or a moiety represented by:




and R¹ represents an alkyl or alkenyl group.

3. The method of Claim 2, wherein R¹ comprises at least 12 carbon atoms.
4. The method of Claim 2, wherein each R² is hydrogen.

12 Apr 2010

2003299972


5. The method of Claim 1, wherein the transduction enhancing agent has the chemical formula:



wherein n is a positive integer.


6. The method of Claim 5, wherein n is 11 or greater.

7. The method of Claim 1, wherein the transduction enhancing agent has the chemical formula:



wherein n is 9 or 11, preferably 11.


8. The method of Claim 1, wherein the transduction enhancing agent has the chemical formula:



wherein n is a positive integer.

2003299972 12 Apr 2010

9. The method of Claim 8, wherein n is 6 or greater.
10. The method of Claim 1, wherein the transduction enhancing agent has the chemical formula:




wherein n is 6.

11. The method of Claim 1, wherein the oncolytic virus is an oncolytic adenovirus.
12. The method of Claim 11, wherein the oncolytic adenovirus is CG8840.
13. The method of Claim 11, wherein the composition comprising the oncolytic virus further comprises docetaxel.
14. The method of Claim 1, further comprising, when the luminal surface of the bladder is contacted with a pretreatment composition before it is contacted with the oncolytic virus, washing the luminal surface of the bladder after contact with the pretreatment composition and before contact with the composition comprising the oncolytic virus.
15. The method of Claim 1, wherein the pretreatment composition further comprises an oxidizing agent selected from the group consisting of hypochlorous acid, hydrogen peroxide, and peroxyacetic acid.
16. The method of Claim 1, wherein the lipophilic substituent comprises an alkane group.
17. The method of Claim 1, wherein the lipophilic substituent is an alkanoic acid residue.


12 Apr 2010

2003299972

18. The method of Claim 1, wherein the transduction enhancing agent has the chemical formula:



where R^1 represents an alkyl or alkenyl group, or wherein R^1 is:



19. A method for treating cancer of the bladder comprising:
contacting the luminal surface of the bladder with a pretreatment composition comprising about 0.01 to about 0.2 % by weight sodium oxychlorosene, either together with a composition comprising an oncolytic virus or before contacting the luminal surface of the bladder with a composition comprising an oncolytic virus.

20. The method of Claim 19, wherein the oncolytic virus is an oncolytic adenovirus.


21. The method of Claim 20, wherein the oncolytic adenovirus is CG8840.

22. The method of Claim 20, wherein the composition comprising the oncolytic virus further comprises docetaxel.

23. The method of Claim 19, further comprising, when the luminal surface of the bladder is contacted with a pretreatment composition before it is contacted with the oncolytic virus, washing the luminal surface of the bladder after contact with the pretreatment composition and before contact with the composition comprising the oncolytic virus.

2003299972 12 Apr 2010

24. A method of treating cancer of the bladder comprising:
contacting the luminal surface of the bladder with a pretreatment composition comprising a transduction enhancing agent having a structure represented by the chemical formula:



wherein x and y are positive integers; wherein the luminal surface of the bladder is contacted with the pretreatment composition either together with a composition comprising an oncolytic virus or before the luminal surface of the bladder is contacted with a composition comprising an oncolytic virus.

25. The method of Claim 24, wherein x is 6 and y is 8 – 10.



26. The method of Claim 24, wherein the oncolytic virus is an oncolytic adenovirus.

27. The method of Claim 26, wherein the oncolytic adenovirus is CG8840.

28. The method of Claim 26, wherein the composition comprising the oncolytic virus further comprises docetaxel.

29. The method of Claim 24, wherein the pretreatment composition further comprises an oxidizing agent selected from the group consisting of hypochlorous acid, hydrogen peroxide, and peroxyacetic acid.

30. A method of treating cancer of the bladder comprising:
contacting the luminal surface of the bladder with a pretreatment composition comprising a transduction enhancing agent having a structure represented by the following general formula (I) or the following general formula (II):

12 Apr 2010
2003299972

wherein x is a positive integer; wherein the luminal surface of the bladder is contacted with the pretreatment composition either together with a composition comprising an oncolytic virus or before the luminal surface of the bladder is contacted with a composition comprising an oncolytic virus.


31. The method of Claim 30, wherein x is 11.
32. The method of Claim 30, wherein the oncolytic virus is an oncolytic adenovirus.
33. The method of Claim 32, wherein the oncolytic adenovirus is CG8840.
34. The method of Claim 32, wherein the composition comprising the oncolytic virus further comprises docetaxel.
35. The method of Claim 30, wherein the pretreatment composition further comprises an oxidizing agent selected from the group consisting of hypochlorous acid, hydrogen peroxide, and peroxyacetic acid.
36. A composition comprising:
a transduction enhancing agent; and
an oncolytic virus;
wherein the transduction enhancing agent is a disaccharide having a lipophilic substituent and wherein the disaccharide is selected from the group consisting of sucrose,

12 Apr 2010


2003299972

lactose, maltose, isomaltose, trehalose and cellobiose, wherein the composition comprises (1) a single composition comprising the transduction enhancing agent and the oncolytic virus or (2) a first composition comprising the transduction enhancing agent and a second composition comprising the oncolytic virus.

37. The composition of Claim 36, wherein the transduction enhancing agent is a compound having the following general formula (I):



wherein X is a sulfur or oxygen atom, each R² is independently hydrogen or a moiety represented by:



and R¹ represents an alkyl or alkenyl group.

38. The composition of Claim 36, wherein the oncolytic virus is an oncolytic adenovirus.

39. The composition of Claim 36, wherein the oncolytic adenovirus is CG8840.

40. The composition of Claim 36, further comprising docetaxel, and wherein the docetaxel is included in the single composition comprising the transduction enhancing agent and the oncolytic virus or in the second composition comprising the oncolytic virus a.

41. The composition of Claim 36, further comprising an oxidizing agent, wherein the oxidizing agent is selected from the group consisting of hypochlorous acid, hydrogen peroxide, and peroxyacetic acid, and wherein the oxidizing agent is included in the single composition comprising the transduction enhancing agent and the oncolytic virus or in the first composition comprising the transduction enhancing agent.

2003299972 12 Apr 2010


42. The composition of Claim 36, wherein the lipophilic substituent comprises an alkane group.

43. The composition of Claim 36, wherein the lipophilic substituent is an alkanoic acid residue.

44. The composition of Claim 37, wherein R¹ comprises at least 12 carbon atoms.

45. The composition of Claim 37, wherein each R² is hydrogen.


46. The composition of Claim 36, wherein the transduction enhancing agent has the chemical formula:



wherein n is a positive integer.

47. The composition of Claim 46, wherein n is 11 or greater.

48. The composition of Claim 36, wherein the transduction enhancing agent has the chemical formula:




wherein n is 9 or 11, preferably 11.

49. The composition of Claim 36, wherein the transduction enhancing agent has the chemical formula:

12 Apr 2010


2003299972



wherein n is a positive integer.


50. The composition of Claim 49, wherein n is 6 or greater.

51. The composition of Claim 36, wherein the transduction enhancing agent has the chemical formula:




wherein n is 6.

52. The composition of Claim 36, wherein the transduction enhancing agent has the chemical formula:



where R¹ represents an alkyl or alkenyl group, or wherein R¹ is:



10.

53. A composition comprising a transduction enhancing agent, wherein the transduction enhancing agent is sodium oxychlorosene, and an oncolytic virus, wherein the composition

12 Apr 2010

2003299972

comprises (1) a single composition comprising the transduction enhancing agent and the oncolytic virus or (2) a first composition comprising the transduction enhancing agent and a second composition comprising the oncolytic virus.

54. The composition of Claim 53, wherein the oncolytic virus is an oncolytic adenovirus.

55. The composition of Claim 53, wherein the oncolytic adenovirus is CG8840.



56. The composition of Claim 53, further comprising docetaxel, and wherein the docetaxel is included in the single composition comprising the transduction enhancing agent and the oncolytic virus or in the second composition comprising the oncolytic virus.

57. The composition of Claim 53, wherein the pretreatment composition further comprises an oxidizing agent selected from the group consisting of hypochlorous acid, hydrogen peroxide, and peroxyacetic acid, and wherein the oxidizing agent is included in the single composition comprising the transduction enhancing agent and the oncolytic virus or in the first composition comprising the transduction enhancing agent.

58. A composition comprising:

a transduction enhancing agent; and
an oncolytic virus;

wherein the transduction enhancing agent has a structure represented by the following general formula (I) or the following general formula (II):



13 Aug 2010

2003299972

wherein x is a positive integer and wherein the concentration of the transduction enhancing agent is less than 0.025 wt% of the composition,

wherein the composition comprises (1) a single composition comprising the transduction enhancing agent and the oncolytic virus or (2) a first composition comprising the transduction enhancing agent and a second composition comprising the oncolytic virus.

59. The composition of Claim 58, wherein x is 11.


60. The composition of Claim 58, wherein the oncolytic virus is an oncolytic adenovirus.

61. The composition of Claim 60, wherein the oncolytic adenovirus is CG8840.

62. The composition of Claim 60, wherein the composition comprising the oncolytic virus further comprises docetaxel, and wherein the docetaxel is included in the single composition comprising the transduction enhancing agent and the oncolytic virus or in the second composition comprising the oncolytic virus.

63. The composition of Claim 58, wherein the pretreatment composition further comprises an oxidizing agent selected from the group consisting of hypochlorous acid, hydrogen peroxide, and peroxyacetic acid, and wherein the oxidizing agent is included in the single composition comprising the transduction enhancing agent and the oncolytic virus or in the first composition comprising the transduction enhancing agent.

64. A composition comprising a transduction enhancing agent and an oncolytic virus, wherein the transduction enhancing agent has a structure represented by the chemical formula:



wherein x and y are positive integers, and wherein the composition comprises (1) a single composition comprising the transduction enhancing agent and the oncolytic virus or

13 Aug 2010

2003299972

(2) a first composition comprising the transduction enhancing agent and a second composition comprising the oncolytic virus.

65. The composition of Claim 64, wherein x is 6 and y is 8-10.

66. The composition of Claim 64, wherein the oncolytic virus is an oncolytic adenovirus.

67. The composition of Claim 66, wherein the oncolytic adenovirus is CG8840.

68. The composition of Claim 66, wherein the composition comprising the oncolytic virus further comprises docetaxel, and wherein the docetaxel is included in the single composition comprising the transduction enhancing agent and the oncolytic virus or in the second composition comprising the oncolytic virus.

69. The composition of Claim 64, wherein the pretreatment composition further comprises an oxidizing agent selected from the group consisting of hypochlorous acid, hydrogen peroxide, and peroxyacetic acid, and wherein the oxidizing agent is included in the single composition comprising the transduction enhancing agent and the oncolytic virus or in the first composition comprising the transduction enhancing agent.

70. A method as claimed in any one of claims 1, 19, 24 and 30 substantially as herein described with reference to any example thereof and/or the accompanying drawings.

71. A composition as claimed in any one of claims 36, 53, 58 and 64 substantially as herein described with reference to any example thereof and/or the accompanying drawings.

15%




FIG. 1A



FIG. 1B

20%



FIG. 1C




FIG. 1D



FIG. 1E

FIG. 1F




FIG. 1G

FIG. 1H




FIG. 2A




FIG. 2B




FIG. 2C



40X

FIG. 3A



100X

FIG. 3B



40X

FIG. 3C



100X

FIG. 3D



40X

FIG. 3E




100X

FIG. 3F




40x

FIG. 4A




100x

FIG. 4B




40x

FIG. 4C



100x

FIG. 4D



40x

FIG. 4E



100x

FIG. 4F




FIG. 5A

FIG. 5B





FIG. 5C

FIG. 5D




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 6D



FIG. 7A




FIG. 7B




FIG. 7C




FIG. 7D




FIG. 8A

FIG. 8B




FIG. 8C

FIG. 8D




FIG. 8E



FIG. 8F



FIG. 8G




FIG. 8H




FIG. 8I



FIG. 8J




FIG. 8K



FIG. 8L




FIG. 8M




FIG. 8N




FIG. 9A




FIG. 9B




FIG. 9C



FIG. 9D




FIG. 9E




FIG. 9F




FIG. 9G



FIG. 9H




FIG. 9I



FIG. 9J




FIG. 9K




FIG. 9L



FIG. 9M




FIG. 9N




FIG. 10A




FIG. 10B




FIG. 11A





FIG. 11B




40x

FIG. 12A



100x

FIG. 12B



40x

FIG. 12C




100x

FIG. 12D



40x

FIG. 12E




100x

FIG. 12F




40x

FIG. 13A




100x

FIG. 13B



40x

FIG. 13C




100x

FIG. 13D



40x

FIG. 13E




100x

FIG. 13F




FIG. 14A



40x

FIG. 14B




100x

FIG. 14C



FIG. 15A



40x

FIG. 15B



100x

FIG. 15C






FIG. 16A



40x
FIG. 16B




100x

FIG. 16C




FIG. 17A



40x

FIG. 17B



100x

FIG. 17C





FIG. 18A



40x

FIG. 18B



100x

FIG. 18C



FIG. 19A



40x

FIG. 19B




100x

FIG. 19C



FIG. 20A



40x

FIG. 20B




FIG. 20C




FIG. 21A




FIG. 21B



40x

FIG. 21C



100x

FIG. 21D





FIG. 22A

FIG. 22B



40x

FIG. 22C



100x

FIG. 22D






FIG. 23A



40x

FIG. 23B




100x

FIG. 23C




FIG. 24A



40x

FIG. 24B



100x

FIG. 24C





FIG. 25A



40x

FIG. 25B




100x

FIG. 25C




FIG. 26A



40x

FIG. 26B



100x

FIG. 26C






FIG. 27A



40x

FIG. 27B



100x

FIG. 27C






FIG. 28A



40x

FIG. 28B




100x

FIG. 28C




FIG. 29A



40x

FIG. 29B



100x

FIG. 29C





FIG. 30A



40x

FIG. 30B



100x

FIG. 30C



FIG. 31A



FIG. 31B



FIG. 31C




FIG. 31D



FIG. 31E



FIG. 32A




FIG. 32B



FIG. 32C